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Pulmonary diseases are the leading causes of mortality globally amongst children under five years of 
age. Economic evaluations (EEs) guide decision-makers on which health care interventions to adopt 
to reduce the paediatric pulmonary disease burden.  
Methods 
We systematically reviewed EEs for paediatric pulmonary diseases published globally between 2010 
and 2020. We searched PubMed, Web of Science, MEDLINE, Paediatric Economic Database Evaluation 
(PEDE), and the Cochrane library. EEs included were specific to paediatric pulmonary diseases in a 
hospital setting and for children aged from zero to six years old. We extracted data items guided by 
the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. We collected 
qualitative and quantitative data which we analysed in Microsoft Excel and R Software. 
Results  
22 studies met the inclusion criteria. Seven of the articles were cost-effectiveness analyses, five cost-
utility analyses, two cost-minimisation analyses, and eight cost analyses. Fourteen studies were 
conducted in high-income countries,  and eight in low-middle-income countries (LMICs). Ten studies 
were on asthma, nine on pneumonia, two on asthma and pneumonia, and one on tuberculosis. Quality 
assessment of the articles revealed some methodological inconsistencies across the articles. 
Conclusion 
Fewer EEs were conducted in LMICs, yet children from these countries are disproportionately affected 
by pulmonary diseases. Developing standardised methods for EEs and conducting more EEs for 
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The use of economic evaluations in informing decisions about health interventions by decision-makers is 
becoming more common as a response to the scarcity of resources in different societies (Weiss and Sullivan, 
2001, Drummond et al., 2015). As health experts develop new strategies to combat disease burden, there is a 
growing need to ensure that the decisions they make are from an informed health economic perspective. 
The proposed study seeks to systematically review economic evaluations for paediatric pulmonary diseases, 
which are the leading cause of morbidity and mortality amongst children (Nair et al., 2010). This study falls 
under a broader study, PediCAP, which is assessing the impact of oral step-down to amoxicillin or co-amoxiclav 
for children with severe community-acquired pneumonia, who have had intravenous antibiotics administered 
to them in a hospital setting. PediCAP is a randomised control trial which will be carried out in hospitals in 
South Africa, Uganda, Zimbabwe, and Zambia. The trial could potentially reduce the length of hospital stay 
(LOS) as well as have an impact on the clinical outcomes for the sick children. Across different groups, 
providers, payers and families, there is a common desire to reduce LOS for reasons which vary from cost-
minimisation, reduction in loss of productive days and minimising exposure to antibiotic-resistant bacteria 
(Pati et al., 2012).  
BACKGROUND TO THE STUDY 
Children are considered a vulnerable group to research, and care needs to be taken so that their rights are not 
violated. There are also ethical considerations when dealing with this group, such as getting informed consent 
from the legal parent or guardian before any economic evaluation can take place. As the methods of 
conducting economic evaluations are continuously being improved, there is still a need to validate the use of 
standard methods in the paediatric population because of the vulnerability of children and other challenges 
that are presented when trying to conduct economic evaluations in children (Ungar and Santos, 2004, Ungar, 





those identified in adult economic evaluations which include; poor adherence to reporting standards, lack of 
transparency, failure to identify perspectives and incomplete costing amongst others (Ungar, 2011).  
Understanding the methods and other aspects of economic evaluation in child health presents a unique 
opportunity to use evidence in informing policymakers, program administrators and other stakeholders who 
are at the forefront of making health care decisions for children. Since the inception of the Paediatric Economic 
Database Evaluation (PEDE), there has been an increase in promoting research in paediatric health economics 
(Ungar and Santos, 2004). Paediatric pulmonary diseases are a leading cause of morbidity and mortality in 
children, with pneumonia resulting in the largest number of childhood deaths globally (Nair et al., 2010). In 
the year 2013, 6.3 million deaths of under five-year-olds were caused by pneumonia, yet early diagnosis and 
treatment in that same time-frame could have averted as many as 600 000 deaths from pneumonia (Abrha et 
al., 2018). Pneumonia and bronchiolitis fall under acute lower respiratory infections and the group worst 
affected by lower respiratory infections are children under the age of five. The reported deaths amount to 704 
000 each year and more than 6 million disability-adjusted life years (DALYs) worldwide (De Benedictis and 
Bush, 2018). 
According to the United Nations (UN) commission on life-saving commodities for children and women, these 
deaths can be prevented or treated by simple and affordable medicines administered before, during and after 
birth (Abrha et al., 2018). Taking steps to control, prevent and cure respiratory diseases are considered as 
being amongst the most essential cost-effective health interventions available (FIRS. Forum of International 
Respiratory Societies, 2017). Respiratory diseases occur in all parts of the world, regardless of the level of 
development. The respiratory diseases held responsible for the highest levels of morbidity and mortality in 
children on a global scale are asthma, acute lower respiratory tract infections (pneumonia and bronchiolitis), 






Below is a summary of three of the diseases that will be considered for purposes of the review. The focus will 
be on pneumonia; however, asthma and pulmonary TB will be searched for and included if any economic 
evaluations focusing on them are found. 
Pneumonia 
Pneumonia is the leading cause of mortality in children under the age of five globally (Ayieko and English, 
2007). The main pathogens which cause pneumonia are the Streptococcus pneumonia (S.pneumoniae), non-
typeable Haemophilus influenza and respiratory syncytial virus (Zhang et al., 2018, Wardlaw et al., 2006).  It 
kills more children under the age of five than AIDS, measles and malaria combined (Wardlaw et al., 2006). Like 
the trend observable in most diseases where the brunt of the burden is borne by the world’s poorest countries, 
half of the deaths from pneumonia are reported in the African continent (Bozzani et al., 2016).  It is estimated 
that there are 156 million new episodes of pneumonia each year worldwide, where 151 million of these are 
found in the low-and middle-income countries (Rudan, 2008). The risk factors for pneumonia include being 
very young (or being very old), living in crowded housing, lack of breast-feeding in infants, low birth weight, 
HIV infection, lack of immunization and exposure to air pollutants (FIRS. Forum of International Respiratory 
Societies, 2017, Rudan, 2008). There is evidence that suggests that effective and appropriate management of 
clinical cases of pneumonia is possible in all settings (Niessen et al., 2009). The main challenge is that these 
interventions aimed at reducing pneumonia morbidity and mortality reach too few children (Wardlaw et al., 
2006). In a report by the World Health Organisation (2019b), they estimated that only one-third of the children 
with pneumonia receive the antibiotics they need. According to the same report, most cases of pneumonia 
require oral antibiotics for their treatment except for instances when the pneumonia is severe, then 
hospitalization is recommended. 
Community-acquired pneumonia is one of the most common paediatric inpatient diagnoses, yet also 
preventable (Pati et al., 2012). Several studies have been conducted to date to make meaningful contributions 
to child health. The “Pneumonia Etiology Research for Child Health” (PERCH) study, for instance, had the 





Another study aimed at improving the understanding of child health was the “Aetiology of Neonatal Infection 
in South Asia” (ANISA) study where the objective was to provide a better understanding of causes of neonatal 
infections in resource constrained countries (Seale and Agarwal, 2018). There are also health economics 
studies that have been carried out which assess the cost-effectiveness of the different interventions to reduce 
pneumonia, such as the pneumococcal conjugate vaccine and other immunizations, reducing indoor pollution, 
nutritional interventions and case management, amongst others (Niessen et al., 2009). This study will 
systematically review the literature to identify which economic evaluations have been performed for 
pneumonia interventions, where have they been done, what still needs to be done, and what can be done 
differently to assist decision-makers in making evidence-based decisions about resource allocation and health 
service provision (Ram Jat and San Sebastian, 2013).  
Asthma 
Asthma is the most common chronic disease amongst children, the symptoms of which are more prevalent in 
children living in high-income countries (Asher and Pearce, 2014). It is defined as “a chronic inflammatory 
disorder of the airways that affects adults and children of all ages” (Braman, 2006). It is estimated that 334 
million people worldwide are affected by asthma; however the actual number is unknown due to some 
unreported cases (FIRS. Forum of International Respiratory Societies, 2017). Despite the prominence of the 
disease in high-income countries, recent trends indicate that there is an increase in its prevalence in low-and 
middle-income countries (Lenney et al., 2018). According to (Asher et al., 2020, Asher, 2010), this can be 
attributed to environmental factors, and lifestyle changes as low-and middle-income countries become more 
urbanised, thus pointing to a reduction in disparities of global asthma prevalence. Genetic predisposition, 
exposure to allergens and air pollution, maternal smoking, and maternal stress, use of antibiotics and dietary 
factors have also been found to play a role in the development of asthma (FIRS. Forum of International 
Respiratory Societies, 2017, Lenney et al., 2018, Subbarao et al., 2009). 
Fewer children die from asthma compared to other paediatric diseases such as pneumonia and tuberculosis, 





in the event of a child having asthma, certain cost implications arise. These include the time spent not involved 
in activities for the child (school and playtime), the cost of treatment and management of the disease (may 
include hospitalisation in severe cases), and the productivity loss for parents or guardian when taking care of 
the sick child (Lenney et al., 2018). From a provider’s perspective, the costs may include; preventive and 
relieving medications, patient education, hospital care and ambulatory services amongst others (Asher and 
Pearce, 2014).  
There is no known way of preventing asthma; however, adopting practices such as not smoking during 
pregnancy is effective in reducing childhood asthma (Subbarao et al., 2009). The use of controller medications 
(for acute relief of symptoms and long-term control of asthma) as a way of preventing attacks is considered 
one of the methods of asthma management (FIRS. Forum of International Respiratory Societies, 2017). Trigger 
avoidance, patient education, immunotherapy and monitoring of symptoms are some of the efforts that can 
be taken to manage asthma (Papadopoulos et al., 2012, Motala et al., 2009). Before the treatment of asthma, 
it needs to be accurately diagnosed. This process involves the identification of a characteristic pattern of 
respiratory symptoms (coughing, wheezing, chest tightening and shortness of breath) which can be achieved 
through; spirometry, bronchial hyper-activity test, peak flow monitoring and chest monitoring (Bush and 
Fleming, 2015, E.D. Bateman et al., 2018).  
Despite having this understanding of the diagnosis and treatment of asthma, the elimination of asthma is still 
a distant vision. To date, studies have been conducted to assess the cost-effectiveness of the different aspects 
involved in the treatment and management of asthma. A scoping review of the literature in PEDE shows that 
asthma is second to pneumonia with regards to the number of economic evaluations that have been 
conducted to date.   
Tuberculosis 
Tuberculosis, caused by Mycobacterium Tuberculosis (TB), is one of the leading causes of death, yet it is a 
treatable infectious disease (Dye, 2006). It is estimated that approximately 15% of the global disease burden 





B et al., 2007). Children from low-and middle-income countries are said to have a twenty-fold risk of infection 
compared to those from high-income countries (Tsai et al., 2013). Studies have also shown that mortality from 
tuberculosis has a strong correlation with socio-economic status, nutritional status, and immunosuppression 
while the top five risk factors for the disease include; diabetes, smoking, HIV infection, harmful use of alcohol 
and undernourishment (Swaminathan and Rekha, 2010, WHO, 2019c).  
According to the Global Impact of Disease report (2017), there are difficulties in diagnosing TB in children. As 
a result, the incidence of the disease in children is often understated. One of the reasons for it being difficult 
to diagnose is that the disease can mimic many of the common childhood diseases such as pneumonia and 
other bacterial infections (Tsai et al., 2013). To by-pass this challenge, diagnosis is often based on exposure 
history in addition to the clinical features presented by the patient (Tsai et al., 2013). Once the disease is 
confirmed, the patient is started on anti-TB medication. It is during the period of antibiotic treatment, where 
patients have a risk of poor medication adherence, that drug-resistant TB may develop (Nelson and Wells, 
2004). 
Some of the strategies that have been employed to date to control and eliminate the disease include 
integrated patient care policies, creating supportive systems, conducting intensified research and increasing 
coverage of the Bacille Calmette Guerin (BCG) vaccine (FIRS. Forum of International Respiratory Societies, 
2017). The WHO guidelines also stipulate that all children who are below the age of five should be traced and 
screened if they have been in contact with a person who tested positive for TB (Swaminathan and Rekha, 
2010). They are also put on isoniazid preventive therapy (IPT) for at least 6 months to reduce their risk of 
contracting tuberculosis (Tadesse et al., 2016).  
 
Sustainable Development Goals (SDGs) and child health 
It is worth mentioning that the WHO, which is prominent in child health, is not the only agency of the United 
Nations that seeks to improve the health and well-being of young children. The United Nations Children’s Fund 





developmental aid to children around the world. In addition to these, the United Nations General Assembly is 
key in ensuring that the children’s needs fall on the global agenda. See for example, the following section 
which discusses how child health falls under the sustainable development agenda.  
In 2015, countries signed a commitment to achieve a set of goals to “ end poverty, protect the planet and 
ensure prosperity for all” (Alfvén et al., 2019). Aimed at reducing infant mortality, sustainable development 
goal three (SDG 3) seeks to “ensure healthy lives and promote well-being for all at all ages” with countries 
being committed to “by 2030, end[ing] preventable deaths of new-borns and children under 5 years of age, 
with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1000 live births and under-
5 mortality to at least as low as 25 per 1000 live births” (WHO, 2020b, Saha et al., 2018, Grove et al., 2015). As 
the risk factors for different diseases change, so do the health strategies aimed at alleviating the disease 
burden worldwide. However, there are variations in the implications of disease burden with respect to the 
direct and indirect costs across various settings (Ehteshami-Afshar et al., 2016). There is still a dearth of studies 
that highlight the variation of these studies across different geographical regions and health care settings 
(Ehteshami-Afshar et al., 2016). There is also a scarcity of economic evaluations that have been conducted for 
paediatric diseases (Kwon et al., 2019). The implications for this could be a lack of evidence-based decision-
making in terms of priority disease resource allocation which could negatively impact the progress towards 
achieving the SDGs. 
Economic evaluations concepts and methods 
In this study, we will be systematically reviewing economic evaluations of paediatric pulmonary diseases. We 
will include full economic evaluations (cost-benefit analysis (CBA), cost-utility analysis (CUA), cost-
effectiveness analysis (CEA), cost-minimisation analysis (CMA)) and partial economic evaluations (cost 
analysis, and cost of illness (COI) studies). Economic evaluation is the comparison of alternative options in 
terms of costs and consequences (Drummond et al., 2015). In a CUA, the “outcomes of alternative procedures 
or programmes are expressed in terms of a single, utility-based unit of measurement” (Drummond et al., 





researchers to capture both the gains in health-related quality of life (HRQoL) and the increased life 
expectancy attributable to a healthcare intervention (Luyten et al., 2016). In calculating QALYs, a person’s 
health state is valued relative to perfect health (value of 1) or death (value of 0), this health state is then 
weighted by the length of time a person spends in this state (O’Reilly et al., 2011). However, in other settings 
where it is difficult to measure the QALY such as in children, the disability-adjusted life year (DALY) is preferred. 
The DALY was developed by the WHO and the World Bank to quantify disease burden and injuries on the 
human population (Gao et al., 2015). DALYs seek to quantify ‘the total years of life lost to premature death 
and the years of life lived with suboptimal health due to any condition that reduces functioning partially or 
fully for a short period or a long duration’ (Chen et al., 2015). The multidimensional outcomes used within CUA 
enable comparisons across diseases, thereby overcoming the limitation of the CEA where outcomes are often 
‘natural’ or disease specific (Kumar et al., 2006).  
The CEA is defined as, “an economic study design in which consequences of different interventions are 
measured using a single outcome, usually in ‘natural’ units (life-years gained, deaths avoided, heart attacks 
avoided or cases detected)” (Wonderling et al., 2011). The results for a CEA may be stated as, “either in terms 
of incremental cost per unit of effect or in terms of effects per unit of cost (life-years gained per dollar spent)” 
(Drummond et al., 2015). CEAs are used when comparing interventions with the same effects. This has been 
cited as one of their major limitations, the reason being, economic evaluations are often used to guide 
decision-makers in making informed decisions about resource allocation, which often requires comparing 
benefits of different programs and assessing the opportunity cost (Drummond et al., 2015). In such instances, 
the CUAs are more applicable because of their generic measure of benefit. The CUA also has limitations 
particularly in valuing utility of children (Kwon et al., 2019). 
In this review, we will also include CBAs which have been performed for paediatric pulmonary diseases.  CBAs 
are studies where, “both costs and benefits are measured in monetary values, making it suitable to evaluate 
interventions occurring inside or outside the health care sector…” (Zweifel and Telser, 2007). This allows for a 
relative comparison of the benefit of intervention(s)/ programme(s) to society. However, in children, this 





There are also some instances where the decision to choose an intervention is solely based on the costs of 
each intervention, and the least costly intervention is adopted (Kumar et al., 2006). This usually occurs when 
the interventions are expected to have a similar outcome, and the deciding factor becomes the cost. This type 
of evaluation is the CMA, which is only possible in instances where prior research has been conducted that 
shows that the two programmes are equivalent in terms of effectiveness (Drummond et al., 2015). 
Partial economic evaluations as earlier indicated include COIs, cost analysis, and cost description studies. A 
cost analysis “compares the costs of two or more alternatives without examining their outcomes to find out 
which is of the alternatives is the least costly option”(Drummond et al., 2015). the most basic type of economic 
evaluation as they  provide only  the costs of the interventions (Gunawardane, 2019).  
With respect to COI, it is “the value of the resources that are expended or forgone as a result of a health 
problem” (Hessel, 2008). It includes health sector costs (direct costs), the value of decreased or lost 
productivity by the patient (indirect costs), and the cost of pain and suffering (intangible costs) (Jo, 2014). COIs 
also provide an estimation of the savings that could be made if the disease were to be eradicated (Costa et al., 
2012). Whilst COI studies can demonstrate which diseases may require more allocation of treatment 
resources, they are limited in their determination of resource allocation as they do not measure health 
outcomes (Segel, 2006).  
STUDY AIMS AND OBJECTIVES 
The proposed study is a systematic review of economic evaluations on different interventions related to 
paediatric pulmonary diseases. These interventions will include different treatment regimens; promotive and 
curative measures; diagnostics and screening; medical devices and technology; and additional support such 
as supplemental oxygen. We are interested in identifying the health economic research that has been carried 
out in the past decade with regards to paediatric pulmonary diseases. 
Research question 





 Which economic evaluations have been done to date on paediatric pulmonary diseases? 
The sub-research questions are: 
 Which type of economic evaluations have been done? 
 When and where were they done? 
 Which pulmonary diseases were assessed in the economic evaluations? 
 At which level of care were these economic evaluations conducted? 
 Has there been an increase or decrease over time in the number of paediatric economic evaluations? 
Aim 
To conduct a systematic review of economic evaluations on the interventions for paediatric pulmonary 
diseases conducted in a hospital setting. 
Objectives 
The proposed study seeks to: 
 provide a qualitative and quantitative description of existing literature on economic evaluations for 
paediatric pulmonary diseases, 
 categorise the methodologies used for the different economic evaluations, 
 describe the health care and geographical settings of the studies included, 
 highlight the timing of studies,  
 describe the types of diseases and the different interventions covered in the economic evaluations, 
 highlight any differences which might exist across the different study settings 
Justification 
The study will be carried out on the premise that the study findings will contribute towards a better 
understanding of the gaps that exist in the economic evaluations of childhood pulmonary diseases. It will also 
offer a description of methods used in the current literature to conceptualise methods for subsequent 





middle- and low-middle income countries to identify any differences which may occur across the various 
settings. The study should ultimately also inform policy from an angle of efficient and equitable resource 
allocation (Thielen et al., 2016). The study is a component of the PediCAP study aiding in the identification of 
some of the issues arising in the field of paediatric community-acquired pneumonia, to better inform the 
progression of the emerging study. The review will include different components of economic evaluations 
such as the costs, clinical effectiveness, cost-effectiveness, or cost-utility analysis for different paediatric 
pulmonary diseases. The diseases that will be considered in the review will include asthma, tuberculosis, and 
pneumonia. The review will only include inpatient-hospital based articles. 
METHODOLOGY 
This section provides details about the inclusion and exclusion criteria that will be used in the selection of the 
articles for the systematic review. It will also have sections on the information sources that will be used to 
identify the articles relevant to the systematic review, the search strategy that will be used, how the data will 
be managed throughout the process, and how the data will be synthesised. Ultimately, the data that will be 
analysed and synthesised in the systematic review should inform policy and most importantly, the PediCAP 
study. Figure 1 is a diagrammatic representation of the research plan showing the different phases of the 
research. The arrow on the far right of the diagram represents the continuous process of informing the 







Figure 1: Research plan 
Eligibility criteria 
The study will include economic evaluations from high-, middle- and low-middle income countries, i.e. globally 
from any setting. The review will include studies of both full economic evaluations (CEA, CUA, CBA, CMA) and 
partial economic evaluations (cost descriptions, cost analysis studies and cost of illness studies) (Murthy et al., 
2017). Only studies reported in the English language, specific to paediatric pulmonary diseases will be included 
in the review. The study will investigate the trends in paediatric health (disease focus and type of economic 
evaluation methodology used) and how these have changed over time. To meet this objective, the review will 






The review will include economic evaluations (EEs) that focus on paediatric or child health (0-6 years) in the 
field of pulmonary diseases. Therefore, the terms child, children, paediatric and neonates will be used 
interchangeably.  
Study settings 
The EEs that will be included will be those which are hospital-based, and of inpatients. That is, EEs conducted 
in non-hospital settings such as clinic-based, school-based, home-based, and other community-based 
interventions will be excluded from the systematic review. 
Interventions  
This systematic review will include economic evaluations that cover different aspects of paediatric pulmonary 
diseases. These aspects will be limited to those conducted in clinical settings, for example, different treatment 
regimens; curative measures; diagnostics and screening; medical devices and technology; and additional 
support such as supplemental oxygen. Different comparators will be considered in the review, such as 
placebos, alternative standards of care as well as do nothing scenarios (Murthy et al., 2017). 
Outcomes 
The outcome measures for this study will be those that are related to measures of cost-effectiveness and cost-
utility. These will include; “Incremental cost per QALY”, “Incremental cost per DALY, “Incremental Cost-
Effectiveness Ratio (ICER)” and natural units such as life years (Drummond et al., 2015). 
Information sources 
Electronic searches from different databases will be conducted to identify the studies which meet the pre-
specified eligibility criteria. The searches will be conducted within PubMed, Web of Science, MEDLINE, PEDE, 
and the Cochrane library. The Cochrane library will be a useful resource in identifying systematic reviews 





Search strategy  
The same search terms will be used for the different electronic databases listed above. The search terms will 
be guided by the following domains: population, intervention, comparator and outcomes (Thielen et al., 2016). 
Across all the electronic databases, there will be the use of keyword searches, MeSH terms, truncation, and 
Boolean operators. The initial step will include developing multiple search terms for each of the domains. 
Under the population domain the following search terms will be used; [“paediatric” OR “paediatrics” OR 
“pediatric” OR “child” OR “children” OR “infant” OR “infants” OR “neonate” OR “neonates”]. The next domain 
will be that of the condition, where the focus of this review is aligned to paediatric pulmonary diseases, with 
conditions such as; [“pneumonia” OR “asthma” OR “pulmonary TB” OR “ bronchiolitis” OR “bronchitis” OR 
“paediatric disease” OR “pediatric disease” OR “respiratory infections”] will be included. For the final domain, 
measures of the outcome will be searched for using the following terms; [“economic evaluation” OR 
“economic eval*” OR “economic*” OR “costs” OR “cost-effectiveness” OR “cost-utility analysis” OR 
“effectiveness” OR “cost-benefit” OR “cost*” OR “cost benefit” OR “cost effectiveness” OR “cost utility 
analysis” OR “CEA”OR “CUA” OR “CBA” ]. The final step in developing the search strategy will be to make use 
of the Boolean operator “AND” to combine the multiple search terms for the domains. 
The search string will include; [“paediatric” OR “paediatrics” OR “pediatric” OR “child” OR “children” OR 
“infant” OR “infants” OR “neonate” OR “neonates”] AND [“pneumonia” OR “asthma” OR “pulmonary TB” OR 
“ bronchiolitis” OR “bronchitis” OR “respiratory infections” OR “paediatric disease” OR “pediatric disease”] 
AND ; [“economic evaluation” OR “economic eval*” OR “economic*” OR “costs” OR “cost-effectiveness” OR 
“cost-utility analysis” OR “effectiveness” OR “cost-benefit” OR “cost*” OR “cost benefit” OR “cost 
effectiveness” OR “cost utility analysis” OR “CEA”OR “CUA” OR “CBA” ]. 
Study records 
One of the characteristics of a systematic review is the reproducibility of the methodology used (Moher et al., 






The economic evaluations that will be included in the study will be managed using the reference manager, 
EndNote X9, Clarivate Analytics. The results from the searches will be exported to and stored in Endnote. A 
shareable library will be created to allow for any stakeholders interested in accessing the articles that were 
used in compiling the systematic review to do so. The search history from the different electronic databases 
utilised will be exported to Microsoft Excel as a mechanism to keep a record of the steps taken during the 
searching process.  
Selection process 
The selection process is a critical stage in the systematic review. It requires careful selection of the evidence 
to be collated to answer the research question. After the searches have been carried out in the different 
electronic databases and exported to EndNote, the studies will be screened for their appropriateness in 
meeting the research purpose according to the inclusion and exclusion criteria. The first stage of the screening 
process will be the removal of duplicates to be followed by the title review. After this will be an abstract 
review. Once the abstract review has been done, the articles will undergo full-text screening, and this will be 
the final step of the screening process. The articles that will be selected for inclusion in the study after the 
screening process will be stored in Endnote. The information that will be extracted from the selected articles 
will entered in a Microsoft Excel spreadsheet. This spreadsheet will be pretested before it is used for extraction 
purposes. Where inclusion or exclusion is unclear, a second researcher will be consulted. 
Data items 
The data items that will be extracted from the articles selected for inclusion in the systematic review are 









Table 1: Data items for extraction 
Table 1 will be used as a tool to extract data from different selected articles. It will be pivotal in the synthesis 
and analysis of both qualitative and quantitative data on economic evaluations on interventions for  paediatric 
pulmonary diseases.  
Data analysis and synthesis 
During the data analysis and synthesis, some relationships will be explored to answer the research questions. 
For the questions, “what economic evaluations have been done to date?” and “has there been an increase or 
decrease in the number of economic evaluations over time?”, we will look at the volume of the publications 
conducted between 2010 and 2020 of economic evaluations for paediatric pulmonary diseases. For the other 
research questions, they will be addressed by studying the relationships that exist between the analytic 
technique (the type of economic evaluation) used and the variable of interest as indicated in figure 2. The 
statistical significance of the different relationships will be analysed using Microsoft Excel and R software (R 
Project, Vienna, Austria). Figure 2 below illustrates the different variables that will be analysed against the 
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choice of economic evaluation. These variables will include the geographical setting, age group, summary 
outcomes, healthcare setting, disease classification, and the intervention type.  
Risk of bias 
To minimise the risk of selection bias in the study, the study will be guided by  the Cochrane guidelines on 
systematic reviews of economic evaluations (Higgins, 2019) and the Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) checklist (Husereau et al., 2013, Drummond et al., 2015). All the articles that 
will be included in the review will be assessed by the researcher for their appropriateness in the study against 
the set of guidelines from the tools listed above. 
Dissemination of findings 
The plan for the dissemination involves the production of a manuscript for a named peer-reviewed journal 
that will be identified during the study. In addition, there will also be the development of a policy brief for 
different groups of key stakeholders. This might be an opportunity for those in decision-making spaces to use 
the evidence from the study to inform their decision-making.  The full report will also be availed to individuals 
and other groups that might be interested in the study findings. The possible groups might include, PediCAP 
group, Ministries of Health, and some non-governmental organisations (NGOs) working in the hospital 
paediatric units. 
Possible difficulties and solutions 
We anticipate facing difficulties in the identification of studies that match the pre-specified criteria. However,  
a second researcher will be enlisted for consultation. Going into the review, we also anticipate having to deal 
with many data collected through the database searches. We have proposed utilising the reference manager 
Endnote to address this challenge. In instances where an article is identified as relevant to the study, but the 





Strengths and limitations 
The main strength of the study methodology is in its inclusivity of studies from different geographical locations. 
This will provide an insight into the various issues regarding paediatric health by region. However, there is a 
limitation in the way that the review will include economic evaluations that fit the pre-specified inclusion 
criteria regardless of their quality. To address these drawbacks, the author will provide a section that will flag 
studies that do not meet the reporting standards of the CHEERS checklist. Another limitation is in the inclusion 
of studies that are reported only in English which might exclude some relevant studies; however, due to 
resource constraints research articles in other languages will not be included. 
 






For this research, the results of the review will be reported in both tabular and non-tabular formats. The results 
will show the most recent studies to the least recent studies on economic evaluations for paediatric pulmonary 
diseases. It will identify which paediatric disease has received the most attention in terms of economic 
evaluations, the aspects which were covered, and get an overall understanding of where some gaps still exist. 
The review will provide a description of the health care settings where the economic evaluations took place, 
e.g., whether it was in a hospital setting (if reported) and the methodologies that were employed.  
Regarding the PediCAP study, where costs and cost-effectiveness data of different strategies for community-
acquired pneumonia will be collected at different hospitals in South Africa, Uganda, Zambia and Zimbabwe, 
this review will help establish the methods that have been used in previous studies to inform the work and 
methodology used in the economic evaluation component of the PediCAP study. 
ETHICAL CONSIDERATIONS 
Since the introduction of the Nuremberg Code and the Helsinki Declaration, there is an increasing awareness 
amongst researchers on the need to uphold ethical standards (Vergnes et al., 2010). Primary researchers who 
interact with human subjects and collect sensitive information need to be particularly aware of issues on 
obtaining consent from their participants, doing no harm and ensuring privacy and confidentiality (Suri, 2020). 
However, in systematic reviews, there are no explicit guidelines on the standard ethical considerations. In this 
section, the discussion will be around the steps that will be taken to ensure that the researchers will be 
reflexive and will adhere to good practices in conducting the review as a way of upholding ethical standards 
in the proposed study. 
Study approval  
The proposed review is a secondary analysis which does not involve human subjects; it does not require 





sought from the School of Public Health and Family Medicine (SPHFM) Departmental Research Committee at 
the University of Cape Town.  
Selected studies 
The proposed study is a systematic review of economic evaluations for paediatric pulmonary reviews. The 
authors of the included studies will be duly acknowledged in the references and the text. This also includes 
the different databases that will be used in identifying the different studies. It is also worth noting that any 
ethical insufficiencies, in reporting the ethical considerations in the studies included for the review, will be 
highlighted. 
Good practices in systematic reviews 
A way of upholding ethical standards in systematic reviews that has been cited is adherence to good practices 
in systematic reviews (Vergnes et al., 2010). These include:  
 Avoiding duplication  
To avoid redundancy, searches will be conducted through the Cochrane Library to identify similar reviews that 
have been carried out and areas where the proposed review can contribute towards or build on existing work 
(Wager and Wiffen, 2011). Where the need presents itself to contact authors that have worked on systematic 
reviews on economic evaluations for paediatric pulmonary diseases, then they will be contacted. A useful 
resource already uncovered to identify the existing literature on paediatric evaluations that will be used in the 
study is PEDE.  
 Author reflexivity 
Author reflexivity is a critical step in ensuring that results are unbiased. It will be the responsibility of the 
author throughout the study to understand their positionality in the study (Yin, 2002). The author throughout 
the study will be aware of the need to communicate the study findings to a broader audience as these findings 
will be disseminated to different groups of stakeholders. Yin’s criteria for ensuring rigour and validity in studies 
will be used in the proposed study. Namely: 





The confirmability of studies will be ensured through providing the relevant information about the different 
articles that will be used in the review and a detailed process on how they will be retrieved in the results 
section of the systematic review.  The steps that will be taken in this study will be recorded in such a way that 
whoever wants to conduct the same study can follow the same steps and come out with the same results 
(Wager and Wiffen, 2011). Also, the knowledge that will be generated from the proposed study could be used 
by future researchers who might be interested in conducting economic evaluations for the same age group 
(what to do or what not to do). 
II. Credibility  
The credibility of the study results will be ensured by following guidelines from different sources 
(triangulation) in terms of best practices in conducting a systematic review (Higgins, 2019), preferred methods 
for reporting systematic reviews (Moher et al., 2015a) and a thorough selection of studies that fit the pre-
specified selection criteria. 
Conflicts of interest 
In the event of any sources of conflict arising, the author will be sure to highlight them. The sources of 
funding for this will also be reported as a means of ensuring transparency (Yin, 2002, Korstjens and Moser, 
2018). Funding is provided for this work through the European Developing Countries Clinical Trials 
Partnership (EDCTP); no conflicts of interest are noted. 
WORK PLAN  
 
 Activity Duration  
Protocol 2 months 
Literature Review 2 months 
Quality assessment of studies 2 months 
Data extraction 2 months 
Data analysis and synthesis 2 months 
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Health has a central position in the United Nations 2030 Agenda for Sustainable Development through 
Sustainable Development Goal (SDG) 3 which seeks “to ensure healthy lives and promote well-being 
for all at all ages” (Barredo et al., 2015). Therefore, investing in children’s health is critical as they 
constitute society’s future human capital. It is from this premise that the health of children is 
enshrined in the Agenda for Sustainable Development (Alfvén et al., 2019). Having children at the 
centre of the SDGs provides them with the protection and the resilience they need to withstand 
emerging global challenges and a constantly evolving disease burden. Whilst significant progress has 
been made on many health fronts since the 2000s, to meet the SDG targets, there is a need to 
accelerate and expand this progress. Efforts to accelerate this progress include paying close attention 
to the death rates of children less than five, which is an essential indicator of child health globally 
(Barredo et al., 2015, Van Malderen et al., 2019). One of the SDG 3 targets is ending mortality from 
preventable causes in children below the age of five and new-borns by 2030. Achieving this target 
requires extensive efforts to ensure that effective interventions in reducing infant mortality are made 
accessible, affordable, and acceptable for all. Countries and the globe at large therefore require more 
robust evidence-based decision-making to inform resource allocation for such interventions. 
Economic evaluations provide an opportunity to inform evidence-based decisions.  
Over the years, economic evaluations have increased in availability and have gained more acceptance 
as a tool for decision-making in health care. This has primarily been attributed to the scarcity of 
resources where decision-makers are increasingly seeking ways in which they can maximise the 
benefits from constrained resources (Kirigia and Asbu, 2013). The decision as to which health care 
intervention to adopt can be well informed by economic evaluations which help to determine the 
intervention which comparatively gives the best value for money (Lamsal and Zwicker, 2017). 
Economic evaluations to date have been conducted for different age-groups and across diverse 





evidence on paediatric pulmonary diseases. The interest in paediatric pulmonary diseases follows 
their emergence as the main causes of morbidity and mortality in the paediatric population (De 
Benedictis and Bush, 2018). Despite these diseases being the leading causes of morbidity and mortality 
of children, they are also often very preventable and manageable (FIRS. Forum of International 
Respiratory Societies, 2017).  
This structured literature review serves as the precursor to a systematic review aimed at answering 
the question, “which economic evaluations have been done to date for paediatric pulmonary 
diseases?”. It aims to inform a broader study, PediCAP. PediCAP has the overarching objective, “to 
optimise antibiotic treatment for children between the ages of 2 months to 6 years hospitalised with 
severe/very severe community-acquired pneumonia in South Africa, Uganda, Zambia and Zimbabwe” 
(Penta, 2020). PediCAP is a clinical trial that will investigate “the impact of oral step-down to 
amoxicillin or co-amoxiclav for children with severe community-acquired pneumonia (CAP), who have 
had intravenous antibiotics administered to them in a hospital setting” (Penta, 2020). Taking this 
approach could potentially reduce the length of hospital stay for children whilst also improving the 
clinical outcomes for the sick children. 
Objectives of the literature review 
This section will present a summary of the literature on economic evaluations, paediatric health, and 
pulmonary diseases. It will highlight some of the topical issues around paediatric pulmonary diseases. 
Also, it will provide a synopsis of the gaps that exist in economic evaluations for paediatric pulmonary 
diseases whilst also acknowledging the work that has been done to date in that field. This literature 
review will also provide an opportunity for the identification of other matters arising in child health 
(pulmonary health) whilst highlighting the policy implications of these issues. 
Literature search strategy 
The strategy involved using search engines (Semantic Scholar and Google Scholar) to identify relevant 





Web of Science and Scopus, keeping in mind that this is a structured review (the systematic review is 
presented in the subsequent dissertation section – Part C). The keywords were “economic evaluations, 
paediatric pulmonary diseases, pneumonia, child health”. Some of the keywords were combined 
during the search. The documents retrieved included policy documents, economic evaluations, 
qualitative and quantitative research, reports, conference proceedings and policy briefs. Documents 
that were included in this structured literature review were those that focused on child health and 
paediatric pulmonary diseases and economic evaluations. We excluded articles or studies reported in 
other languages besides English and those whose focus was not on paediatric pulmonary health.  
SUMMARY AND INTERPRETATION OF LITERATURE 
 Economic evaluations: An overview 
In making decisions, policymakers are often concerned with assessing the opportunity cost of the 
decisions they make. Opportunity cost refers to the value of the benefit foregone by taking a different 
course of action (Drummond et al., 2015). Decision-makers are interested in this value of the benefit 
foregone because its effects influence how health care resources are spent. In other words, the costs, 
and the benefits of different courses of action should be weighed before any decision can be made, 
and economic evaluation is a tool we can use to aid this process. An economic evaluation is referred 
to as “the comparative analysis of alternative courses of action in terms of both their costs and 
consequences” (Drummond et al., 2015). Economic evaluations are divided into full economic 
evaluations, such as cost-benefit analysis (CBA), cost-utility analysis (CUA), cost-benefit analysis (CBA) 
and cost minimisation analysis (CMA); and partial economic evaluations which encompass cost of 
illness studies, cost analysis and cost description studies (Higgins, 2019).  
The evidence that is retrieved from these economic evaluations is referred to as economic evidence, 
and policy-makers across countries use this evidence. In addition to the economic evidence being used 
by policy-makers, the evidence is also relied upon by pharmaceutical companies, health care 





intended influences the perspective taken (e.g. health care or societal perspective). Generally 
speaking, pharmaceutical companies require this economic evidence to make decisions on which 
drugs or devices to manufacture, health care facilities use this evidence to seek profit maximisation, 
and the patients are interested in this evidence to guide their decision on the utilisation of services to 
improve their health (Frick et al., 2012a). Economic evidence is particularly useful in health care 
decision-making, and it would be useful to consider the different techniques which are employed in 
economic evaluations and the value that each of them has. This will be covered in the following 
sections, including a discussion on the value of including evidence from economic evaluations into 
systematic reviews. This section will also illuminate some of the facilitators and barriers that exist in 
conducting economic evaluations across different age-groups and settings. 
Systematic reviews of economic evaluations 
In the sections leading to this one, the importance of economic evaluation in informed decision-
making has been emphasised. In an article by Frick et al. (2012b), the importance of incorporating 
economic evaluation data into systematic reviews for health care interventions is explained. They also 
indicate that taking this route would be useful in strengthening evidence-based decision-making. The 
use of systematic reviews over the years has increased because they are considered as pillars for 
evidence-based health care (Selçuk, 2019). The methodological rigour of systematic reviews has been 
cited as one that facilitates their applicability in minimising bias, maximising contribution to science, 
providing a foundation for practice guidelines and use as a reference standard for getting clinical 
research into real-world practice (Munn et al., 2018, Moher et al., 2015b, Sutherland, 2004). 
Systematic reviews are: “a method/process/protocol in which a body of literature is aggregated, 
reviewed and assessed while utilising pre-specified and standardised techniques” (Selçuk, 2019). 
Initially, systematic reviews were common for “synthesising evidence from randomised controlled 
trials investigating health treatment efficacy” (Gomersall et al., 2015). Over time, their methodology 





questions and support evidence-informed decision-making. The evolving methodology resulted in 
different types of reviews which include methodological reviews, prognostic reviews, effectiveness 
reviews, aetiology reviews, prevalence reviews, diagnostic reviews, experiential reviews, 
psychometric reviews, expert reviews and cost/economic evaluation reviews (Munn et al., 2018). The 
choice of systematic review type is guided by the research question that the researcher seeks to 
answer. In this instance, the research question was one on economic evaluations performed for 
paediatric pulmonary diseases. This largely influenced our decision to select the cost/economic 
evaluation type of systematic review.  
The Cochrane handbook for systematic reviews and other handbooks that provide guidelines for 
conducting systematic reviews have been adapted to include guidelines specific to systematic reviews 
for economic evaluations (SREEs) (Higgins et al., 2019). The guidelines differ in their presentation 
across the different handbooks, but what is consistent is their portrayal of economic evaluation 
reviews as tools for assessing the costs, processes, contexts, or procedures of different interventions 
(Munn et al., 2018, Higgins, 2019). More specifically, SREEs can be used with the aim of; quantifying 
the differences between competing interventions for the same condition; showing the effect of 
adjusting the delivery of an intervention at different intervals, different age-groups or risk groups; 
evaluating the effectiveness of new technologies; identifying conditions which need to be met to 
achieve optimum benefits of an intervention; and identifying patient, health service provider, or 
government preferences (Pignone et al., 2005, Tacconelli, 2010). SREEs have been cited as an efficient 
mechanism to synthesise evidence on cost-effectiveness which can help in avoiding research waste, 
enabling sponsors, governments, and investigators to maximise their efforts in meeting set targets 
(Jacobsen et al., 2020).  
The ability of systematic reviews to synthesise large amounts of evidence is one of their strengths 
(Gomersall et al., 2015). What has been questioned is the synthesis of economic evidence in 
systematic reviews. This synthesis is made complex by the variability that exists across different health 





variations can be observed in the different payment mechanisms for health care and in terms of health 
service delivery across country health systems  (Jacobsen et al., 2020, Nixon et al., 2001). From this 
premise, one of the arguments against the value of SREEs is that the differences in the costs and 
utilisation of resources vary by country. This might translate to the same interventions producing 
different results across diverse settings (Gomersall et al., 2015). This variability could potentially 
undermine the transferability (“the extent to which the results of a study hold true for a different 
population or setting”) and generalisability (“the extent to which the results of a study can be 
generalised to the population from which the sample was drawn”) of the results obtained from the 
SREEs (Wijnen et al., 2016). SREE are also prone to confirmation bias. Confirmation bias in research is, 
“when an individual looks for and uses the information to support their own ideas” (Simundić, 2013). 
Whether it is unintentional or intentional, the effects of bias can diminish the value of SREEs to 
decision-makers and other users significantly (Wijnen et al., 2016, Liberati et al., 2009). It is therefore 
important to conduct SREEs with methodological rigour to minimise any potential bias. To date, tools 
such as PRISMA (preferred reporting items for systematic reviews and meta-analyses) have been 
developed to improve the quality and standardise the reporting of systematic reviews. 
Standardising how systematic reviews are reported is of paramount importance, especially for the 
end-user. How systematic reviews are conducted differs from structured literature reviews. The 
critical differences between the two are observed in the methods of obtaining literature and the 
selection and extraction of material and data for the review (Okoli, 2015). Some of the defining 
features of systematic reviews and its conduct include; articulated objectives, predetermined 
inclusion and exclusion criteria to establish the eligibility of studies, predefined search strategy to 
identify all the eligible studies, a thorough process of screening and selecting relevant studies, 
appraisal or quality assessment of the selected studies, data extraction, analysis of the data extracted 
from the selected studies, presentation and interpretation of the results, and ensuring transparency 
in the reporting of the methodology used to conduct the review (Munn et al., 2018, Cronin et al., 





selecting and evaluating the data. The criteria for literature selection in structured literature reviews 
are not always made known to the reader (Petticrew and Roberts, 2008). 
SREEs can be time-consuming, costly, and are best conducted while working in teams (Tacconelli, 
2010). The dearth of economic evaluations also raises concerns amongst reviewers interested in 
conducting SREEs that the outcome of their systematic review could be limited rather than producing 
quality evidence that could contribute in getting research into real-world practice (Gomersall et al., 
2015). According to (Drummond et al., 2010), “...the real contribution of a systematic review of 
economic evaluations may not be to produce a single authoritative result, but to help decision-makers 
understand the structure of the resource allocation problem that they are addressing and the impact,  
on  the  overall  result  of  the  main parameters”. 
Economic evaluation concepts and methods 
The value of economic evaluations in informing decision-makers on resource allocation in a manner 
that maximises the benefits and minimises waste have been emphasised in the earlier text. This 
section will summarise the different concepts and methods that characterise economic evaluations. 
Summaries will be provided for the different types of full economic evaluations (CUA, CMA, CBA, CEA). 
Full economic evaluation is not a single research method, but rather, “a framework for structuring 
specific decision problems” (Shemilt et al., 2008). Therefore, the choice of economic evaluation to be 
adopted is also determined by the economic question that the study seeks to answer. According to 
(Drummond et al., 2015), full economic evaluations studies aim to “describe, measure and value all 
competing courses of action, including the respective resource inputs and outcomes”. In contrast, 
partial economic evaluations (cost of illness studies, cost analysis and cost description studies) do not 
“provide explicit comparisons between different courses of action with regards to costs and 
consequences” (Shemilt et al., 2008). However, they do provide some insights to help understand the 






Economists often use the term technical efficiency, which occurs when the minimum amount of input 
produces the maximum amount of output (Ahmed et al., 2019). Generally, this is the scenario that is 
ideal for policy-makers. The CEA allows policy-makers to compare different interventions to see how 
best they can achieve technical efficiency within a given budget (Miller and Trent, 2001, Perkins et al., 
2015). A CEA measures the effect of an intervention in unidimensional units, also known as natural 
units (life-years gained, number of infections averted) (McIntosh and Luengo-Fernandez, 2006). 
Where one intervention costs less and is more effective, then the decision to adopt that intervention 
is straight forward (Clyne and Edwards, 2002). It often becomes difficult to decide on the appropriate 
course of action when one intervention is more effective, whilst also more costly.  
To assist with the decision-making, costs per unit effect of the competing interventions are compared 
(Drummond et al., 2015). These are compared as a ratio known as the incremental cost-effectiveness 
ratio (ICER). The ICER is calculated by dividing the differences in the cost of the competing alternatives 
by the difference in their benefits. The ICER is then compared to an appropriate cost-effectiveness 
threshold (CET) or to results for similar interventions and contexts, to establish whether the 
intervention gives value for money. To look at the affordability of the intervention, a next step is 
required, which is assessing the budget for the given interventions. This is commonly referred to as 
the budget impact analysis (BIA). A BIA is carried out by taking “the true unit cost of an intervention, 
multiplying it by the number of people for whom the intervention is for to provide a picture of the total 
budget required to fund the intervention” (Yagudina et al., 2017). From this calculation, it can be 
determined whether high-value interventions are affordable.  
To re-iterate, economic evaluations are a useful tool in guiding resource allocation. This often 
translates to decision-makers having to compare the benefits of different programs and assessing 
their opportunity cost. Unfortunately, the CEA does not fully accommodate this as it only measures 
interventions with the same outcome and does not allow for cross-sector comparisons. The CUA is 





 Cost-utility analysis 
CUAs and CEAs are the same in many ways, with their main difference being how they measure 
outcomes/effects. In CEA, as already mentioned, the measurement of outcomes is in natural units. In 
contrast, in CUAs, the outcomes are utility adjusted, where utility refers to a “patient's preference for 
a particular health outcome” (Nancy et al., 2014). The multidimensional outcome is reported as either 
a disability-adjusted life year (DALY) or a quality-adjusted life-year (QALY). CUAs have gained 
popularity over the years in health care decision-making because they enable comparison of health 
benefits for different health care interventions by using a single measure of health benefit (the QALY 
and the DALY) (McIntosh and Luengo-Fernandez, 2006). 
The DALY is a summary measure of health which combines morbidity and mortality into a single 
measure (Chen et al., 2015). DALYs quantify “the total years of life lost to premature death and the 
years of life lived with suboptimal health due to any condition that reduces functioning partially or fully 
for a short time or a long duration” (Chen et al., 2015). The QALY is a combination of the quantity and 
quality of life that a person can live in a given state (Goodacre, 2002). Put in other words, a QALY is, 
“a generic health metric that allows researchers to capture both the gains in health-related quality of 
life (HRQoL) and the increased life expectancy attributable to a health care intervention” (Luyten et 
al., 2016). To calculate the QALY, the quality of life is measured on a scale ranging from zero to one, 
where zero indicates death and one indicates perfect health (O’Reilly et al., 2011, Goodacre, 
2002).  The final stage in calculating the QALY involves multiplying the amount of time in years over 
which the quality assessment applies by its quality weighting  (Drummond et al., 2015). The quality 
weighting is usually determined by generic preference-based measures such as the EuroQol 5 
Dimension (EQ-5D) (Nancy et al., 2014).  
Like CEA, CUA assesses relative efficiency using a ratio, which in this case is the incremental cost-utility 
ratio (ICUR) amounting to a cost per QALY gained or cost per DALY averted (Palmer et al., 1999). The 





for money. The CET describes the amount of money that, if removed from the health care system, 
would result in one less unit of health being generated (Woods et al., 2016). An intervention is 
considered as cost-effective if its ICUR or ICER is less than the CET. When the ICER is greater than the 
CET or to the results of similar studies where no country threshold exists, then the benefits are 
insufficient in comparison to the cost, thus the intervention cannot be cost effective (Woods et al., 
2016). 
To assist with the interpretation of an ICUR, a cost-effectiveness plane can be used as illustrated in 
the figure below. The comparator is plotted at the origin, the horizontal axis is the difference in 
outcomes between the interventions while the vertical axis represents the difference in total costs 
(Cleary et al., 2006). If the ICER falls in quadrant II and quadrant IV, the decision is straight forward, 
yes, and no respectively. In quadrant II the new intervention has lower costs and more benefits, unlike 
in quadrant IV where it has more costs and less benefits. Quadrants I and III are more difficult to decide 
from because they require the decision makers to make a trade off. In quadrant III the new 
intervention is less costly with lower outcomes and in quadrant I, the new intervention is more costly 
but with more outcomes (Cleary et al., 2006). Some countries have adopted the use of CETs to try and 







Figure 3: Cost-effectiveness plane (Hounton and Newlands, 2012) 
Cost-benefit analysis 
Following the definition by (Drummond et al., 2015), a CBA is, “a type of economic evaluation where 
costs and benefits are both valued in monetary terms”. It is the broadest form of economic evaluation, 
where results are presented in terms of net benefit (Razzouk, 2017). The net benefit put in other 
words, is the benefit of an intervention (in monetary terms) minus the cost of an intervention (Perkins 
et al., 2015). The essence of a CBA therefore is, if the benefits of a project / programme / intervention 
outweigh the project / programme / intervention costs, then the project / programme / intervention 
is recommended (Johansson and Kriström, 2018). CBA is useful in measuring both allocative and 
technical efficiency in different sectors, including the health sector, where allocative efficiency relates 
to “the distribution and mix of resources within the health sector in comparison with other sectors of 
the economy” and technical efficiency is concerned with “maximising the output produced from the 
given inputs/resources” (Athanassopoulos and Gounaris, 2001).  
Nonetheless, the applicability of CBAs in health care has been criticised due to the difficulties in 





The most common approach used in a CBA to quantify health in monetary units is the willingness to 
pay approach (WTP) which measures the degree to which patients value improvements in their health 
based on how much they would be willing to pay (Johansson and Kriström, 2018, Clyne and Edwards, 
2002). Essentially, WTP estimates the “monetary value of an outcome in the absence of an actual 
market for that outcome” (Razzouk, 2017). It creates a measure by asking a sample, which aims to be 
representative of the population. However, as WTP is influenced by values, preferences, income, as 
well as state of health, this is not always a perfect fit (Nancy et al., 2014). Consequently, CBA is not as 
prominent in health care as the CEA and CUA. Another type of economic evaluation which is not so 
prominent is the CMA, which will be discussed in the subsequent section.  
 Cost minimisation analysis 
A CMA is used in instances where clinical studies have shown the effectiveness of the competing 
alternatives to be broadly equivalent (Drummond et al., 2015). This is the simplest form of economic 
evaluation where the costs of two or more competing options under consideration are compared to 
establish the least costly intervention (Nancy et al., 2014, NICE, 2014). Essentially, the CMA can be 
described as cost analysis. The major drawback of CMAs is that they do not include the intended or 
unintended impacts from different health care interventions and only assume equivalent outcomes 
(Clyne and Edwards, 2002).  
Partial economic evaluations 
The previous sections described the uniqueness of the four main types of full economic evaluations 
(CUA, CMA, CBA, CEA). We shall now briefly describe the different types and characteristics of partial 
economic evaluations. Partial economic evaluations do not make explicit comparisons between 
alternative interventions in terms of both costs and consequences (Higgins, 2019). For example cost 
analyses are considered the most basic form of economic evaluation as they only offer comparisons 
on the costs of interventions and not on outcomes (Gunawardane, 2019, Segel, 2006). Similarly, cost 





allocation as they do not measure health outcomes (Segel, 2006). The fundamental goal of COI studies  
is “ to evaluate the economic burden that illness imposes on society as a whole health studies” (Jo, 
2014). They provide an estimation of the savings that could be made if the disease were to be 
eradicated (Costa et al., 2012).  
In addition to understanding the uniqueness of each type of economic evaluation, it also key to note 
the differences in methodological approaches of economic evaluations across age-groups, 
intervention settings and the type of intervention. Important to methodology is also noting whether 
the authors collected data on opportunity costs and include these to calculate the intervention cost, 
and how they did their discounting. 
Concerns around economic evaluations 
The growth in the use of economic evaluations in informing health care decisions has made difficulties 
in using standard methods for adults and children more relevant (Ungar, 2011). The observations 
made being that children are unique individuals, not just little adults, and as such, they require 
methods specific to them. The biological differences between the two groups mean that the results 
of economic evaluations of adults cannot be easily applied to children (Keren et al., 2004). Children 
differ from adults in their development, dependency, patterns of resource use and patterns of health 
and disease (Ungar and Gerber, 2010). These cognitive differences are relevant to economic 
evaluations as they affect how economic evaluations are conducted and what the results mean across 
different groups. Take for instance, in pharmaceuticals, the differences in medication dose and risk-
benefit profiles between children and adults may produce different cost-effectiveness results (Keren 
et al., 2004). Children also have a high dependency on their parents and guardians, and often they 
stand in as proxies in valuing children’s health (Oliveira et al., 2020). In a study by Ungar (2011), she 
argues that while parents may be reliable sources in reporting physical limitations on behalf of 
children, they might not be the best proxies in reporting more subjective outcomes such as the 





old (Keren et al., 2004). For children over six years old, evidence shows that they can use the tools 
specifically developed for children to measure their health-related quality of life (HRQoL) (Stevens, 
2010). However, questions have also been raised around these child-specific tools as to whether the 
dimensions of HRQoL for a 9-year-old are the same as those of a 16-year-old or if they differ. 
Apart from the technical issues around economic evaluations for child health, there are also ethical 
considerations for this vulnerable group (Pitt et al., 2016). Since the Helsinki declaration in 1964, 
ethical guidelines in clinical research have been acknowledging the child’s right as a research subject 
or patient to participate in their health care decision-making (Villena Sarmiento and Vieira Da Motta, 
2013). Before minors can participate in any research, informed consent needs to be given by the 
parents or legal guardians of the children. In addition, children over six years of age are also expected 
to give their assent to participate in the research (Villena Sarmiento and Vieira Da Motta, 2013, Pitt et 
al., 2016). At this age, children are expected to have a degree of reflexive judgement, and as such, 
their views towards their health also matter (Stevens, 2010). The views of the children towards their 
health should be considered at all levels of decision-making. It is, therefore, of paramount importance 
that when using economic analyses to inform resource allocation, the interests and the rights of 
children should be safeguarded and protected.  
Despite a plethora of considerations that are unique to child-related research, economic evaluations 
for children are not spared on some of the deficiencies that compromise the quality of adult economic 
evaluations. In a study by Ungar and Gerber ((2010), they summarised these deficiencies in economic 
evaluations to include; lack of clarity on study perspective, incomplete costing, difficulties in 
generalisability, reliance on intermediate outcomes and lack of sensitivity analyses. The study 
perspective in economic evaluations is essentially used to describe the decision-maker for whom the 
costs and consequences being measured in the economic evaluation is meant to inform (Drummond 
et al., 2015). Baharin et al. (2017) suggested that the societal and provider/health care sector 





The provider/health care perspective is inclusive of all health care expenditure by the provider, that 
is, private, or public (Carias et al., 2018). On the other hand, a societal perspective includes all the 
costs and health benefits, not considering who bears the costs or who receives the benefits (Sanders 
et al., 2016). The societal perspective includes costs and benefits which go beyond the health sector. 
The Second Panel on Cost-Effectiveness in Health and Medicine recommended this perspective, citing 
welfare economics principle (Carias et al., 2018). This scope goes beyond the one which was 
recommended by the first panel, which focused on family spill-over effects (Carias et al., 2018). Whilst 
the societal perspective is important, for it to be a useful reference case in CEAs, there is need to 
further efforts in developing standard measures of costs and outcomes (Sanders et al., 2016).  
The lack of generalizability of economic evaluations poses a challenge for decision-makers. The main 
concern here being the difficulties in using the results of economic evaluations across different 
contexts and settings.  A central challenge that is faced by those conducting or using economic 
evaluations in low-middle income countries (LMICs) is the lack of accessible high-quality data which 
can be attributed in part to fragmented health systems (Pitt et al., 2016). The unavailability of local 
data coupled with the differences in health care resources and practices raises questions about the 
relevance of informing health care decisions based on economic evaluations conducted elsewhere. 
For example, Hausler et al. (2006) conducted a study on cost-effective measures for controlling human 
immunodeficiency virus (HIV) and tuberculosis (TB) in South Africa. They highlighted that their findings 
could not be generalised to other parts of Africa because of the differences in salary costs of personnel 
in South Africa which are relatively high in comparison to other parts of Africa (Hausler et al., 2006).  
In addition to underscoring the importance of the different aspects of economic evaluations for child 
health (pulmonary health), it is also helpful to situate child health in a broader context, the global 





Child Health: An overview 
With countries world over having committed to the SDGs, good health is essential to meeting these 
global targets. The SDGs were adopted in 2015 by the United Nations to “promote healthy lives and 
well-being for all children” (WHO, 2019a). The SDG goal 3 is to end preventable deaths of new-borns 
and under-5 children by 2030 and its targets include, “reducing new-born mortality to at least as low 
as 12 per 1 000 live births in every country” and “reducing under-five mortality to at least as low as 25 
per 1,000 live births in every country” (WHO, 2019a).  Child mortality rates are key indicators for both 
global health and child health (Van Malderen et al., 2019). According to a report by the World Bank 
(2020), child mortality rates have halved from the year 1990 to 2020 with a notable decline in the 
under-five mortality rates. They dropped from 12.5 million per year to 5.3 million in 2018 alone 
(WorldBank, 2020). 
Whilst this decline in mortality rate is commendable, with every region world-wide observing a decline 
in child mortality, the world is not on track to reach the SDG targets for child mortality (Max et al., 
2019). Current evidence points to an estimated 15 000 children dying every day, which is an alarming 
statistic (World Bank(2020);(Max et al., 2019). The place where a child is born and resides plays a role 
in the survival of that child. Sub-Saharan Africa has the highest under-five mortality rates in the world, 
with one child in 13 dying before they reach their fifteenth birthday (Ester et al., 2011). This rate is 
more than sixteen times higher than the one in 199 average recorded in high-income countries. 
Meeting the SDG target on reducing under-five mortality by 2030 would reduce under-five mortality 
rates significantly. The World Health Organization (WHO) purported that meeting the under-five 
mortality target by 2030 would reduce the deaths by 10 million worldwide. However, efforts would 
need to be focused on Sub-Saharan Africa and South-East Asia to reduce 80% of these deaths (WHO, 
2019a). 
Paediatric pulmonary diseases are the leading cause of death and ill-health amongst children below 





As paediatric health professionals and organisations seek ways to respond to the diseases that 
threaten the lives of children, they are sometimes faced with global situations that hinder their 
progress. The main challenge now which may hinder efforts to achieve the 2030 SDG targets for health 
is the COVID-19 pandemic. The available evidence thankfully points to COVID-19 having a limited 
impact on the mortality of children. Compared to the other age-groups, the direct impact of COVID-
19 infection has been milder on children (UN, 2020). Drawing from the preliminary findings of studies 
conducted in China and the United States of America, the hospitalisation rates for symptomatic 
children are much lower (10 to 20 times less) than the middle-aged and even lower (25 to 100 times 
less) than the elderly (the most affected age-group) (UN, 2020).  
Despite evidence pointing to children being less susceptible to COVID-19, the indirect effects of 
COVID-19 are most likely to affect the health and well-being of children. Whilst evidence shows that 
infants are not the face of the pandemic, they risk being amongst its biggest victims (UNICEF, 2020a). 
Child survival might be compromised stemming from weakened health systems, reduced household 
income, and disruptions in health-seeking behaviours such as not obtaining vaccines for children 
(which could lead to pneumonia in children in 2021) and other preventative medicines (UNICEF, 
2020a). COVID-19 has caused a global economic recession and based on the historical correlation 
between global domestic product (GDP) growth and infant mortality in LMICs, a tragic  number of 
deaths could occur in 2020 and 2021. Such an occurrence could potentially threaten the progress 
made in the last 2 to 3 years in reducing infant mortality within the space of a year (UN, 2020). 
In crises, deep-seated inequalities and vulnerabilities of some population groups are exposed. The 
vulnerability of children is a subject that is often raised in paediatric research because of children’s 
dependence on adults (Ungar and Gerber, 2010). The physical and psychological cognitive states of 
children often mean that their parents or guardians guide the health care decision-making for children 
(Petrou, 2003). When disasters strike, children need to be protected from these impacts. Some of the 
efforts in defending children amid a pandemic include ensuring the availability and accessibility of 





difficult decisions about which interventions to implement and what the health and economic effects 
of these interventions are. Economic evaluations play an essential role in providing some of the 
guidance and intervention projections required by policy-makers. Policy-makers need to find a balance 
in realising COVID-19 specific gains whilst at the same time ensuring overall protection of global 
health.  
As COVID-19 ravages the world, diseases that threaten the health of children still exist, even more so 
with the disruptions in health services caused by the pandemic. Reduced access to medicines, vaccines 
and other essential health services threatens efforts made in combating diseases such as pneumonia, 
asthma and tuberculosis, which are the leading causes of infant mortality globally (FIRS. Forum of 
International Respiratory Societies, 2017). The following sections discuss the aetiology, diagnosis, 
disease burden, treatment, prevention, and control of the diseases mentioned above (pneumonia, 
asthma, and tuberculosis). Gaining an understanding of the different aspects of these diseases is 
instrumental in the identification of gaps which may currently exist whilst also highlighting areas which 
might need further research.  
Paediatric pulmonary diseases: An overview 
The previous section mentioned that the place where a child is born is key in determining the survival 
of that child. In a report by the WHO, while significant progress has been made globally in lowering 
child mortality, some disparities still exist in under-five mortality across regions and countries (WHO, 
2019a), with South Asia and Sub-Saharan Africa being the regions in the world with the highest under-
five mortality rates as earlier mentioned. The mortality rates experienced in LMICs can be attributed 
to limited access to care, and fewer interventions in place to improve care compared to high-income 
countries (Izadnegahdar et al., 2013). Pneumonia is the leading cause of morbidity and mortality in 
children under the age of five globally despite the advances made in preventative and management 
strategies (FIRS. Forum of International Respiratory Societies, 2017). In 2018, approximately 802 000 





With less than a decade left to realise the global commitment (SDG3 targets) towards the health of 
children, a sense of urgency emerges. In a report by (UNICEF, 2020c), they estimated that if the current 
progress in scaling up pneumonia-related health interventions was maintained, up to 14.5 million 
children would be saved, including 5.9 million from pneumonia by 2030. Hence the concern for the 
COVID-19 pandemic derailing progress.  
In this section we discussed why the focus on pneumonia is important globally and some of the 
strategies that have been employed and are still to come in ending preventable deaths from 
pneumonia by 2025 following Global Action Plan for the prevention and control of Pneumonia (GAPP). 
The goal for 2025 is “to reduce deaths from pneumonia to fewer than 3 children per 1000 live births” 
(WHO, 2020a). The importance of addressing the causes and effects of pneumonia for sustainable 
development cannot be understated. Additionally, attention should be paid to some of the other 
causes of morbidity and mortality in children under the age of five. Asthma and tuberculosis are some 
of the diseases which impede the lives of children under the age of five.  
Asthma 
Asthma is a chronic condition affecting between 1-18% of the population in different countries (GINA, 
2018). It afflicts approximately 334 million people globally, with its prevalence being on the rise in the 
last three decades (FIRS. Forum of International Respiratory Societies, 2017, Asher and Pearce, 2014). 
Despite the disease being dominant in affluent countries, recent trends indicate that there has been 
an increase in its prevalence in LMICs (Lenney et al., 2018).  In terms of the global ranking of DALYs in 
children, asthma is among the top 20 chronic conditions (Asher and Pearce, 2014). It disrupts daytime 
activities, sleep, school and leads to anxiety amongst parents, families, and other guardians (Lenney 
et al., 2018).  
Asthma is an incurable lifelong disease. However, through the provision of quality-assured essential 
medicines, it can be effectively controlled (FIRS. Forum of International Respiratory Societies, 2017). 





control (GINA, 2018). Inhaled bronchodilators are also on the list, though unfortunately, not everyone 
who has asthma can access these medicines due to their lack of availability or lack of affordability in 
certain countries (FIRS. Forum of International Respiratory Societies, 2017). Apart from the lack of 
available medicines, there are other predisposing factors which impede asthma patients from 
receiving effective treatment. Amongst these are the misconceptions about the disease which prevent 
people from using appropriate treatment. 
Henceforth, making improvements in the knowledge and understanding of asthma amongst children 
and their families should be integral in the management of asthma. In so doing, patients and their 
families are better equipped to adopt lifestyles which allow for the improved management of the 
disease. Some of the strategies to control asthma include; trigger avoidance, minimising smoke 
exposure, immunotherapy, and monitoring of symptoms (Papadopoulos et al., 2012). Fewer children 
die from asthma compared to other paediatric diseases such as pneumonia and TB, and consequently, 
the burden imposed by this disease is sometimes overlooked (Asher and Pearce, 2014). In LMICs, there 
is a need for advocacy campaigns to increase governmental understanding of the long-term socio-
economic burden caused by failure to diagnose asthma and the lack of effective treatment (Lenney et 
al., 2018). The outcome from this could be a change in attitude in addressing childhood asthma in the 
future.  
This section on asthma highlighted the fact that fewer children die from asthma compared to 
pneumonia and TB. Whilst the section on pneumonia touched on the morbidity and mortality 
associated with the disease, it is also critical to highlight the burden imposed on children by TB.  
Tuberculosis 
TB remains a public health concern worldwide despite longstanding efforts to eliminate it as one 
(Cunnama et al., 2020).  The burden of TB in children is understated because of the challenges in 
obtaining an accurate diagnosis for this group, particularly in LMIC settings (Perez-Velez and Marais, 





were children, which was assumed to be an under-estimate because of the difficulties in diagnosing 
TB in children (FIRS. Forum of International Respiratory Societies, 2017). TB in children has not been a 
big public health priority despite it being a leading cause of morbidity and mortality amongst children 
globally (Nelson and Wells, 2004, Mandalakas et al., 2013a). A possible reason for this is that children 
contribute little to TB transmission compared to adults (Tsai et al., 2013).  
TB incidence and prevalence vary by the WHO geographical regions. In 2017, the WHO regions of 
South East Asia, and Africa accounted for up to 70% of the global TB (MacNeil et al., 2019). However, 
the proportion of TB cases among persons living with HIV in Africa was higher than it was in South-
East Asia (MacNeil et al., 2019). TB is prevalent in poor and marginalised populations, and HIV is often 
the key driver of the disease in these areas (Thomas, 2017). Children from LMICs are said to have a 
twenty-fold risk of infection in comparison to those from high-income countries (Tsai et al., 2013). 
Some of the strategies employed to try and control and eliminate the disease include; integrated 
patient care policies, creating supportive systems, conducting intensified research and increasing 
coverage of the Bacille Calmette Guerin (BCG) vaccine (FIRS. Forum of International Respiratory 
Societies, 2017). The WHO guidelines also stipulate that all children who are below the age of five 
should be traced and screened if they have been in contact with a person who tested positive for TB 
(Swaminathan and Rekha, 2010). They are also put on isoniazid preventive therapy (IPT) for at least 
six months to reduce their risk of contracting tuberculosis (Tadesse et al., 2016). In countries with high 
TB burden, blanket IPT programmes were found to be cost-effective in TB prevention (Mandalakas et 
al., 2013a). 
If the United Nations SDGs and WHO End TB Strategy targets for 2030 and 2035 are to be met, there 
is a growing need to intensify efforts to improve TB diagnosis, treatment, and prevention (MacNeil et 






The role of economic evaluations in informing decisions is one that should not be understated. 
Throughout this discourse, their role in guiding resource allocation was emphasised. What also 
emerged were the difficulties in conducting economic evaluations in children due to their cognitive 
differences, among other reasons. The cognitive differences impact how economic evaluations are 
conducted as there is still no gold standard for conducting economic evaluations in children. The lack 
of standardised tools, the vulnerability of children, and ethical considerations when conducting 
research for children are some of the challenging issues which emerge when looking at paediatric 
health. Another facet in paediatric health is the burden of paediatric pulmonary diseases on children. 
Paediatric pulmonary diseases are the leading cause of morbidity and mortality amongst children. 
Their burden on children is exacerbated based on where in the world the child is born and resides. 
These diseases disproportionately affect children from LMICs. There are some important questions 
which arise from this discourse, which if answered correctly, could make a significant contribution to 
the synthesis of previous work as well as economic evaluations for paediatric pulmonary diseases 
going forward. The questions are:  
 Which economic evaluations have been done to date on paediatric pulmonary diseases?  
 How have these economic evaluations been done?  
 When and where were they done?  
 Which diseases did the economic evaluations cover?  
 At which level of care were these economic evaluations conducted?  
 Has there been an increase or decrease over time in the number of paediatric economic 
evaluations? 
By addressing the above questions, the findings could contribute towards a better understanding of 
the gaps that exist in the economic evaluations of childhood pulmonary diseases. Findings from these 





methods for subsequent economic evaluations for paediatric diseases. The consideration of economic 
evaluations from HICs and LMICs may aid in identifying any differences which may occur across the 
various settings. Against this background, the study findings could be used ultimately to inform policy 
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Pulmonary diseases are the leading causes of mortality globally amongst children under five years of 
age. Economic evaluations (EEs) guide decision-makers on which health care intervention to adopt to 
reduce paediatric pulmonary disease burden.  
Methods 
We systematically reviewed EEs for paediatric pulmonary diseases published globally between 2010 
and 2020. We searched PubMed, Web of Science, MEDLINE, Paediatric Economic Database Evaluation 
(PEDE), and the Cochrane library. EEs included were specific to paediatric pulmonary diseases in a 
hospital setting and of children aged from zero to six years old. We extracted data items guided by the 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. We collected 
qualitative and quantitative data which we analysed in Microsoft Excel and R Software. 
Results  
22 studies met the inclusion criteria. Seven of the articles were cost-effectiveness analyses, five cost-
utility analyses, two cost-minimisation analyses, and eight cost analyses. Fourteen studies were 
conducted in high-income countries, eight in low-middle-income countries (LMICs). Ten studies were 
on asthma, nine on pneumonia, two on asthma and pneumonia, and one on tuberculosis. Quality 
assessment of the articles revealed some methodological inconsistencies  across the articles. 
Conclusion 
Fewer EEs were conducted in LMICs, yet children from these countries are disproportionately affected 
by pulmonary diseases. Developing standardised methods for EEs and conducting more EEs and for 
paediatric pulmonary diseases in LMICs could allow for more evidence-based decision-making. 
Keywords  










Paediatric pulmonary diseases are the leading causes of morbidity and mortality amongst children 
under the age of five, particularly in low-and-middle-income countries (LMICs) (1, 2). The burden of 
asthma is higher in high-income countries (HICs) than in LMICs, while the opposite is true for 
pneumonia and tuberculosis (TB) (3). Decision-makers the world-over are constantly facing the 
challenge of resource constraints in their endeavours to curtail the burden of disease imposed on 
children by pulmonary diseases. Over the years, economic evaluations (EEs) have increased in 
availability and have gained more acceptance as tools to aid in decision-making in health care. EEs 
provide some guidance as to which health care intervention to adopt by comparing the interventions 
to assess which alternative provides the best value for money (4).  
This systematic review is part of a broader study, PediCAP, which is looking into the impact of oral 
step-down to amoxicillin or co-amoxiclav for children with severe community-acquired pneumonia 
(CAP), who have had intravenous antibiotics administered to them in a hospital setting (5). PediCAP is 
a randomised control trial which will be carried out in five hospitals in South Africa, Uganda, 
Zimbabwe, and Zambia. The trial could potentially reduce the length of hospital stay (LOS) as well as 
have an impact on the clinical outcomes for the sick children.  
This study aimed to systematically review EEs for paediatric pulmonary diseases conducted globally 
from 2010 to 2020. Our objectives are to: 
 Provide a qualitative and quantitative description of existing literature on EEs for 
paediatric pulmonary diseases, 
 
 Categorise the methodologies used for the different EEs, 
 
 Describe the health care and geographical settings of the articles included, 
 
 Highlight the timing of articles,  
 
 Describe the types of diseases and the different interventions covered in the EEs, 
 








We conducted a systematic review of EEs (published literature) for paediatric pulmonary diseases 
within five electronic databases: PubMed, Web of Science, MEDLINE, Paediatric Economic Database 
Evaluation (PEDE), and the Cochrane library. We made use of keyword searches, MeSH terms, 
truncation, and Boolean operators. Our keywords were paediatrics, pulmonary disease, and EEs. The 
variations we used for paediatrics were, [“paediatric” OR “paediatrics” OR “pediatric” OR “child” OR 
“children” OR “infant” OR “infants” OR “neonate” OR “neonates”]. For pulmonary disease we used, 
[“pneumonia” OR “asthma” OR “pulmonary TB” OR “bronchiolitis” OR “bronchitis” OR “paediatric 
disease” OR “pediatric disease” OR “respiratory infections”]. Lastly, for economic evaluations, we used 
[“economic evaluation” OR “economic eval*” OR “economic*” OR “costs” OR “cost-effectiveness” OR 
“cost-utility analysis” OR “effectiveness” OR “cost-benefit” OR “cost*” OR “cost benefit” OR “cost 
effectiveness” OR “cost utility analysis” OR “CEA” OR “CUA” OR “CBA” ].  
The search string format was: 
 ["paediatric" OR "paediatrics" OR "pediatric" OR "child" OR "children" OR "infant" OR "infants" OR 
"neonate" OR "neonates"] AND ["pneumonia" OR "asthma" OR "pulmonary TB" OR "bronchiolitis" OR 
"bronchitis" OR "respiratory infections" OR "paediatric disease" OR "pediatric disease"] AND ; 
["economic evaluation" OR "economic eval*" OR "economic*" OR "costs" OR "cost-effectiveness" OR 
"cost-utility analysis" OR "effectiveness" OR "cost-benefit" OR "cost*" OR "cost benefit" OR "cost 
effectiveness" OR "cost utility analysis" OR "CEA" OR "CUA" OR "CBA"].  
Inclusion criteria 
We included both full EEs (cost-effectiveness analysis (CEA), cost-utility analysis (CUA), cost-benefit 
analysis (CBA), cost-minimisation analysis (CMA)) and partial EEs (cost descriptions, cost analysis and 





between the years 2010 and 2020. The EEs included in the review were specific to paediatric 
pulmonary diseases, comprising inpatients aged from zero to six years old. For study setting, we 
adopted a global standpoint and included EEs conducted in high-, middle- and low-income countries.  
Also, only EEs conducted in inpatient hospital settings were included. We incorporated EEs that 
covered different aspects of paediatric pulmonary diseases such as different treatment regimens, 
curative measures, diagnostics and screening, medical devices, and additional support such as 
supplemental oxygen. We encompassed EEs reporting outcome measures relating to measures of 
cost-effectiveness, and these included the incremental cost per quality-adjusted life-year (QALY) 
gained, the incremental cost per disability-adjusted life year (DALY) averted, as well as incremental 
cost-effectiveness ratios (ICERs) reported in natural units.  
Exclusion criteria 
Articles excluded from the review were those reported in languages other than English. EEs which 
were conducted in outpatient hospital settings and in other settings such as clinic-based, school-
based, home-based, or community-based were excluded. Furthermore, we excluded articles which 
did not meet the pre-defined age-group (i.e., those articles whose study population were exclusively 
above six years of age). 
Selection process 
In the first stage of the selection process, we removed duplicates in EndNote X9 Software (Clarivate 
Analytics). We did this both electronically and manually. The screening of the papers was done in three 
stages: title screening, abstract screening, and full-text screening. These stages are represented 
diagrammatically in the PRISMA diagram, Figure 1. The selection process was carried out by one 
reviewer who was in consultation with a second reviewer where study eligibility was unclear.  
Data management 
After the selection process, we stored the articles which met the eligibility criteria in a shareable folder 






We developed an extraction tool in Microsoft Excel using the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) checklist as a guide to identifying the data items to be 
extracted. The extraction tool was then pre-tested for its relevance and appropriateness to the study 
before being used. To do this, we tested out the data extraction template on five articles. The variables 
extracted were author, year, project title, journal name, funder, study perspective, duration, setting, 
intervention and comparator, currency reported and currency year, exchange rate, type of EE, 
discounting ( whether there was discounting and the rate used), sensitivity analysis (if there was 
sensitivity analysis done and which type of analysis), ethics approval, informed consent, unit costs, 
outcome measures and ICERs.  
Data synthesis and analysis 
We adopted a convergent mixed-methods approach (6), combining both qualitative and quantitative 
data. For the qualitative assessment, we used a data analysis framework designed during the protocol 
development stage (Figure 2). The framework allowed for the comparison between the type of 
economic evaluation (outcome variable) and other variables of interest (geographical setting, 
summary outcome, healthcare setting, disease, type of intervention) by positioning the outcome 
variable at the centre of analysis. For the quality assessment, we utilised the CHEERS, 24-point 
checklist for assessing the reporting standards of the studies included in the review (7).  
We conducted our quantitative data analysis in Microsoft Excel (2016) and R software (R Project, 
Vienna, Austria) using the user interface of RStudio. We analysed the volume of publications, the 
hospitalisation costs, and ICERS. All costs which were not reported in USD were converted to USD 
using the exchange rates for the study year (8). We inflated the costs to 2019 USD using the World Bank 






The study is a secondary analysis which did not involve human subjects. It, therefore, did not require 
ethical approval. However, we obtained ethical approval from the Human Research Ethics Committee 
(HREC) at the University of Cape Town (UCT), reference number HREC 587/2020. 
RESULTS 
We retrieved 1470 articles from the searches conducted. Duplicates were removed both manually and 
electronically, and 1159 articles remained. Following the screening by title and by abstract, 945 of the 
1159 articles were excluded. We then screened the full text of the remaining 214 articles and 22 
articles met the full inclusion criteria (Figure 1). A description of the characteristics of each study 
included in the systematic review is found in Table 1. Of the 22 articles included, 14 were from HICs, 
and 8 were from LMICs. Amongst these, seven were CEAs, five were CUAs, two were CMAs, and eight 
were cost analyses (see table 2). Figure 2 shows the distribution of type of EE by the timing of 
publication.  
Using our data analysis framework (Figure 3), we identified that there were 10 articles on asthma, 
nine on pneumonia, two on both asthma and pneumonia and one on tuberculosis (TB). Articles which 
covered asthma were predominantly from HICs, pneumonia articles were evenly distributed between 
HICs and LMICs, and the only TB study was from an LMIC (Table 2). The interventions for these diseases 
included diagnostic tests, operational guidelines, antibiotic use (oral vs intravenous), inhaled 
corticosteroids and supplementary oxygen.   
We extracted hospitalisation costs and ICERs, where relevant, for all articles included in the systematic 
review. Table 3 summarises the methodological characteristics of the included articles. It shows the 
costing data, sensitivity analysis, informed consent, outcome measures, discount rate, hospitalisation 
costs (in USD) and ICERs (in USD). 77% (17/22) of the articles reported hospitalisation costs, and 71% 
(10/14) of the full EEs reported ICERs. The median hospitalisation cost per day for the articles reviewed 





For the methodology, three articles adopted a patient perspective, 14 a provider perspective and five 
a patient and provider perspective. The costing for 12 of the articles was done prospectively, and for 
the other 10, it was retrospective. We also assessed the reporting of informed consent in the included 
articles that reported a prospective record review and found that only 25% explicitly reported 
informed consent. With regards to sensitivity analysis, 64% (14/22) of the articles reported performing 
sensitivity analysis and the other 36% (8/22) did not. Of those that reported on sensitivity analysis, 11 
specified the type of sensitivity analysis which was used; the most common being a one-way sensitivity 
analysis, reported by 55% (6/11) of these articles. Table 4 shows the results of the quality assessment 
of each study.  
Our findings indicated that, of the six articles which span more than twelve months, only one study 
reported discounted costs. Articles which discounted their costs discounted at a 3% discount rate(16, 
29) which is agreeable with the 0-5% standard in cost-effectiveness literature (37).We also used our data 
analysis framework to identify the outcome measures. These were reported in the articles as natural 
units, QALYs and DALYs. The natural units reported were, emergency department (ED) visits averted 
(5), life-years gained (1), complications avoided (1), and symptom-free days (1). Two articles reported 
QALYs gained and three reported DALYs averted. 
We also used our data analysis framework (figure 3) in conjunction with the CHEERS checklist (table 
4) to assess the quality of the articles we included in the review.  Some of the methodological 
limitations that we identified in the included articles were the lack of country specific data, the 
variability of costs in diverse settings, heterogeneity limitations, and model assumption biases. Some 
articles considered only public provider profiles and not private provider profiles because of the 
unavailability of data from private providers. We had to make a subjective assessment of these 
findings as the articles were unclear about this. Some authors also reported lack of data on societal 
costs on TB in comparison to those from a healthcare perspective(6). Regarding measures of health 





as the study (30). Also, some authors used utility measures collected for children over the age of five as 
estimates for those below the age of five (30).  
 
 





Table 1: Study characteristics 




Disease(s)  Intervention(s)  Comparator(s) 




mPCR tests Rapid Antigen 
Tests 
Chen, H. H. 
(10) 
2019 Patient Ethiopia Pneumonia Oral antibiotics Not reported 
Krupp, N. L. 
(11) 













Dor, A. (13) 2018 Provider and 
Patient 












2017 Provider Uganda, South 
Africa, Zambia, 
Zimbabwe 












2016 Provider Malawi Pneumonia PCV 13 Pre-intervention 
Razi, C. H 
(18) 
2015 Provider Turkey Asthma Nebulisation Placebo 
Andrews, A. 
L. (19) 




Chu, S. M. 
(20) 




Floyd, J. (21) 2015 Provider Uganda Pneumonia PO1, PO2 IMCI 
Petrou, S.(22) 2014 Provider 
and Patient 
UK Asthma Nebulisation Standard 
treatment 
Krebs, S. E. 
(32) 
2013 Provider USA Asthma Nebulisation Standard 
treatment 
Char, D. S. 
(24) 




Powell, C. (25) 2013 Patient UK Asthma Nebulisation Placebo 
Andrews, A. 
L. (26) 
2012 Provider and 
Patient 







USA Asthma Oral antibiotics Oral antibiotics 




E. I. (29) 











Table 2: Study setting by disease  
 Asthma Pneumonia Asthma and 
Pneumonia 
TB Total 
High-income 9 3 2 - 14 
Low-middle-
income 
1 6 - 1 8 
Total 10 9 2 1 22 
 
 













Table 3: Methodological characteristics 












costs per day 
(USD) 
ICERS (USD) 
Kitano, T. (9) 2020 Cost analysis Prospective NR Stated- no 
informed 
consent 
NR 12  NR  1278,9  NR 
Kitano, T. (9) 2020 Cost analysis Prospective NR Stated- no 
informed 
consent 
NR 12  NR  1158,3  NR 
Chen, H. H. (10) 2019 Cost analysis Retrospective One-way Not stated NR 12  NR  13,92  NR 
Chen, H. H. (10) 2019 Cost analysis Retrospective One-way Not stated NR 12  NR  55,68  NR 
Chen, H. H. (10) 2019 Cost analysis Retrospective One-way Not stated NR 12  NR  162,4  NR 
Krupp, N. L. (11)
  
2018 Cost analysis Retrospective NR Not stated NR >48 NR NR NR 
von Schoen- 
Angerer, T. (12) 
2018 Cost minimisation analysis Prospective NR Not stated ED visits 
averted 
18  NR   NR -216,14 





12  NR  1067,82 31,08 





12  NR  1067,82 32,19 
Ceyhan, M. (14) 2018 Cost analysis Retrospective Probabilist
ic 
Not stated NR 12  NR  1945,8  NR 





12  NR   NR 43,18 





12  NR   NR 211,95 





12  NR   NR 45,5 





12  NR   NR 11,55 
Debes, A. K. (16) 2017 Cost-effectiveness analysis Retrospective Multi-way Not stated Life years 
gained 





Debes, A. K. (16) 2017 Cost-effectiveness analysis Retrospective Multi-way Not stated Life years 
gained 
NR 3%  NR 156,24 
Debes, A. K. (16) 2017 Cost-effectiveness analysis Retrospective Multi-way Not stated Life years 
gained 
NR 3%  NR 228,16 
Bozzani, F. M. (17) 2016 Cost analysis Retrospective One-way Stated- 
informed 
consent 
NR 3  NR  6,42 NR  
Razi, C. H. (18) 2015 Cost analysis Retrospective NR Stated- 
informed 
consent 
NR 28  NR  299  NR 
Andrews, A. L. (19) 2015 Cost-effectiveness analysis Prospective Probabilist
ic 
Not stated ED visits 
averted 
12  NR  2030,4  NR 
Chu, S. M. (20)
  
2015 Cost analysis Retrospective NR Not stated NR 30 NR NR NR 
Floyd, J. (21) 2015 Cost-utility analysis Prospective NR Not stated DALY 
averted 
NR  NR  196,3 18,12 
Floyd, J. (21) 2015 Cost-utility analysis Prospective NR Not stated DALY 
averted 
NR  NR  9,06 24,16 
Petrou, S. (22) 2014 Cost utility analysis Prospective NR Not stated QALY 
gained 
28  NR  285,36 337,02 
Krebs, S. E. (23) 2013 Cost analysis Prospective NR Not stated NR 12  NR  123,76 NR  






>48  NR  122,85  NR 






>48  NR  58,05  NR 





NR  NR  1549,29 355637,52 
Andrews, A. L. (26) 2012 Cost-effectiveness analysis Prospective Two-way  Not stated ED visits 
averted 
NR  NR  7244,64  NR 
Andrews, A. L.(27) 2012 Cost-effectiveness analysis Prospective Two-way  Not stated ED visits 
averted 
NR  NR  7244,64  NR 





NR  NR  2857,19 -3033,31 
Broughton, E. I. 
(29) 
2011 Cost utility analysis Retrospective One-way Not stated DALY 
averted 
24 3% 280,17 -396 
Lorgelly, P. K. (30) 2010 Cost minimisation analysis Prospective One-way Not stated ED visits 
averted 






Table 4: Quality assessment using CHEERS checklist 
Lead author Reference 
year 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Kitano, T. 2020 No Yes Yes Yes Yes Yes Yes Yes No Yes No No Yes No No No No No Yes No No Yes Yes No 
Chen, H. H. 2019 No Yes Yes Yes Yes Yes Yes No No No No No Yes Yes No No Yes No No Yes No Yes No No 
Krupp, N. L. 2018 No Yes Yes Yes Yes Yes Yes No No No No No Yes No No No No Yes No No No Yes No No 
von Schoen-Angerer, T. 2018 No Yes Yes Yes Yes Yes Yes Yes No Yes Yes No Yes No No Yes No No No No No Yes No No 
Dor, A. 2018 Yes No Yes Yes Yes Yes Yes Yes No Yes No Yes Yes Yes No No No No Yes No No Yes No No 
Ceyhan, M. 2018 No Yes Yes Yes Yes Yes No Yes No Yes No No Yes No No No No Yes Yes No No Yes Yes No 
Zhang, S. 2017 Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No Yes Yes Yes No Yes Yes Yes Yes No Yes Yes No 
Debes, A. K. 2017 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes No No Yes Yes Yes Yes Yes Yes Yes Yes No 
Bozzani, F. M. 2016 No Yes Yes Yes Yes Yes Yes Yes No No No No Yes No No No No No Yes No No Yes Yes No 
Razi, C. H. 2015 No Yes Yes Yes Yes Yes Yes Yes No Yes No No Yes No No No No No No No No Yes No No 
Andrews, A. L. 2015 Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No Yes Yes Yes Yes Yes Yes No No No Yes No No 
Chu, S. M. 2015 No Yes Yes Yes Yes Yes Yes Yes No Yes No No Yes No No No Yes Yes No No No Yes No No 
Floyd, J. 2015 No Yes Yes Yes Yes Yes Yes No No No Yes No Yes No Yes No Yes Yes Yes Yes No Yes Yes No 
Petrou, S. 2014 Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No No Yes Yes Yes Yes No Yes Yes No 
Krebs, S. E. 2013 No Yes Yes Yes Yes Yes Yes No No Yes No No Yes Yes No No No No Yes No No Yes No No 
Char, D. S. 2013 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No No Yes Yes No No No No No No No Yes No No 
Powell, C. 2013 Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No Yes Yes No 
Andrews, A. L. 2012b Yes Yes Yes Yes Yes Yes Yes No No Yes No No Yes Yes Yes Yes Yes Yes Yes No Yes Yes No No 
Andrews, A. L. 2012a Yes Yes Yes Yes Yes Yes Yes Yes No Yes No No Yes Yes Yes Yes Yes No No Yes No Yes No No 
Doan, Q. 2011 Yes Yes No Yes Yes Yes Yes Yes No Yes Yes No Yes No Yes No Yes Yes Yes Yes No Yes No No 
Broughton, E. I. 2011 Yes Yes Yes No Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes No Yes Yes Yes Yes No Yes No No 
Lorgelly, P. K. 2010 Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No Yes Yes No No Yes Yes No Yes No Yes Yes No 
Key: Yes = reported in full or partially; No = not reported. 
Checklist: 1. Title; 2. Abstract; 3. Introduction 4. Target Population; 5. Setting and Location; 6. Study Perspective; 7. Comparators; 8. Time Horizon; 9. Discount Rate; 10. Choice of health outcomes; 11a. Measurement 
of effectiveness (single study-based estimates); 11b. Measurement of effectiveness (synthesis-based estimates); 12. Measurement of performance-based outcomes; 13a. Estimating Resources and Costs (single study-
based economic evaluation); 13b. Estimating Resources and Costs (model-based economic evaluation); 14. Currency, Price, Conversion; 15. Model Choice; 16. Assumptions; 17. Analytical Methods; 18. Study Parameters; 
19. Incremental Costs and Outcomes; 20a. Characterizing Uncertainty (single study based economic evaluation); 20b. Characterizing Uncertainty (model-based economic evaluation); 21. Heterogeneity; 22. Study 





Our systematic review indicates that there were more partial EEs (cost-analysis) than there were full 
EEs. The cost analysis is the most basic form of (partial) EE as it assesses only the costs of the 
intervention and provides no information on the outcomes (31). In terms of the full EEs, there were 
more CEAs than there were CUAs and more CUAs than there were CMAs. With regards to decision-
making, the CEA has limitations in that it only allows for comparison within diseases and not between 
diseases due its uni-dimensional outcome measure. This makes it difficult to evaluate the benefits of 
an intervention across different diseases. The CUA on the other hand allows for cross-comparison 
because of its multi-dimensional outcome measure. 
The findings from this study showed that there were more EEs conducted in HICs than there were in 
LMICs. These findings were consistent with those from a study by Ungar (32), where they noted that 
whilst there was an increase in the number of EEs globally, there were more EEs reported in HICs than 
there were in LMICs. We could attribute this to the resource-constraints in LMICs as economic 
evaluations require funding for them to be conducted. 
For the distribution of EEs for asthma, pneumonia and TB, asthma articles were predominantly from 
HICs. This contrasted with pneumonia and TB which had more articles from LMICs. We could attribute 
the dominance of asthma articles in HICs to asthma being a disease of affluence (33). In the case of 
pneumonia, it disproportionately affects less-affluent countries(3), which could explain the wider 
distribution of EEs for pneumonia inpatient interventions in LMICs.  
Another interesting aspect of the review was that we only found one TB study for the zero to six age 
group, yet TB incidence is high in LMICs(3). This could potentially be explained by the fact that TB is 
largely an outpatient disease, and our systematic review comprised only inpatient studies. Another 




We were also interested in understanding the different perspectives adopted in the articles. There 
were more articles which adopted the provider perspective, followed by the societal perspective 
(provider and patient perspective) and lastly, solely the patient perspective. This is despite the patient 
and provider perspective being recommended by the First and Second Panel on Cost-Effectiveness in 
Health and Medicine (36). Part of this could be the cost of conducting EEs from both perspectives. The 
five articles which adopted both a provider and patient perspective were from HICs (9, 13, 22, 26, 27), those 
which adopted a patient perspective were from HICs(25, 30) and LMICs (10). The provider perspective was 
the most common in all settings (11, 12, 14-24, 28, 29). 
Our review also summarised the methodological approaches that were employed in the different 
articles included in the review. The notable differences in the reporting of discounting limits study 
comparability and the interpretation of study findings. Cost data were collected both prospectively 
and retrospectively with more articles reporting prospective cost data collection. In the CUA articles, 
more articles reported DALYs averted as outcome measures than they reported QALYs gained. This 
could be attributed in part to the difficulties in measuring utility in children for QALYs (32). The DALYs 
averted reported were mostly in LMICs compared to HICs. We also identified a gap in the reporting of 
informed consent in the articles included in the review. 
Concerns have been raised in the literature regarding methodological approaches in child-related 
research (31). In this review, only a few of the articles reported informed consent. Our findings were 
also consistent with literature on the challenges that exist in health state valuation in paediatric 
economic evaluation (32). Our review revealed that in the absence of a health utility measure validated 
across the childhood spectrum resulted, some authors had to use utility measures collected for those 
above the age of five as estimates for those below the ages of five (30). Thus, making a case for the 
need to have validated health utility measures (child-specific questionnaires) across the childhood 




We also analysed our study findings as they relate to PediCAP. There was one study which was closely 
linked to PediCAP, assessing the impact of “oral versus IVV [intravenous] antibiotics for community-
acquired pneumonia” (30) in children in a high-income setting. The results from this study indicated 
that the cost of in-patient stay made the greatest contribution to the total cost of care (30) . There were 
also some articles conducted in the countries where PediCAP will be run (Zambia, Uganda, Zimbabwe, 
and South Africa)(15, 16, 21). In the study by Zhang et.al (15), they found child-pneumonia management as 
detailed in the standard World Health Organisation (WHO) guidelines to be cost-effective. Making a 
case on the importance of PediCAP. 
It is worth mentioning the study limitations. The systematic review only EEs conducted in a hospital 
setting and of inpatients. Therefore, this data may not be generalizable to other service delivery 
platforms that are widely utilized and necessary to meet the Sustainable Development goals. There 
was also a missed opportunity to analyse the trends in methodological approaches over time as the 
review only included published literature between 2010-2020 due to practicality. The inclusion of 
published literature and excluding grey literature is also another limitation of this study. 
CONCLUSION 
The study set out to summarise EEs that have been conducted for paediatric pulmonary diseases 
globally. There were more partial EEs conducted than there were full EEs. The EEs were more 
prominent in HICs than they were in LMICs. Consequently, this meant that there were more articles 
for asthma than there were for pneumonia and TB.  
Whilst there is a steady increase in the number of EEs conducted for paediatric health, there is still a 
dearth of studies for EEs conducted in hospital settings for paediatric pulmonary diseases. Meanwhile, 
these are the leading causes of under-five mortality globally. Also, there were fewer EEs published in 
LMICs compared to HICs. However, the evidence from EEs conducted in HICs cannot be used to inform 




affected by pulmonary diseases. The differences in the reporting of methodological approaches also 
made the comparison across the studies difficult. 
We, therefore, assert the need to develop standardised methods of conducting EEs for paediatric 
pulmonary diseases in LMICs to inform evidence-based decision-making. Potentially addressing the 
social and economic burden imposed by paediatric pulmonary diseases, particularly in less well-off 
groups.  
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SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS FOR PAEDIATRIC PULMONARY DISEASES
INTRODUCTION 
The health of children has a central position in 
achieving sustainable development (1). One of 
the Sustainable Development Goal 3 targets is 
ending mortality from preventable causes of 
newborns and children below the age of five by 
2030.  Achieving this target calls for ensuring 
the availability, affordability, and acceptability 
of interventions which are all essential to child 
health. Governments, therefore, require 
robust evidence to inform resource allocation 
for such interventions. 
Economic evaluations (EEs) provide an 
opportunity to inform evidence-based decision 
making as they are, “the comparative analysis 
of alternative courses of action in terms of both 
their costs and consequences” (2). EEs to date 
have been conducted for different age-groups 
and across diverse settings. However, what 
remains scarce in literature is a consolidation 
of the health economic evidence on paediatric 
pulmonary diseases. The interest in paediatric 
pulmonary diseases follows their emergence 
as the main causes of morbidity and mortality 
in the paediatric population (3). 
ABOUT THE STUDY 
The study systematically reviewed EEs for 
paediatric pulmonary diseases published 
globally between 2010 and 2020 and of in-
patients in hospital settings. It provided a 
qualitative and quantitative description of 
existing literature on EEs for paediatric 
pulmonary diseases. Furthermore, it 
categorised the methodologies used for the 
different EEs and described the health care and 
geographical settings of the studies included.  
Also, it highlighted the timing of studies and 
described the types of diseases and the 
different interventions covered in the EEs. 
Finally, it highlighted the differences existing 
across the various study settings. 
METHODS 
We conducted our searches in five different 
databases, retrieving 1470 articles. We 
removed duplicates electronically and 
manually. We then screened these documents 
by title, by abstract and finally by full text using 
our pre-defined selection criteria. Only articles 
reported in the English language, conducted in 
hospitalised settings, published from 2010-
2020 and of children between the ages of 0-6 
years old were included in this systematic 
review. The selection process was carried out 
by one reviewer who was in consultation with 
a second reviewer for all the steps, including 
where study eligibility was unclear. The next 
stage was data extraction. We developed a 
tool in Microsoft Excel, which was pretested to 
assess its appropriateness before using it. To 
analyse the qualitative data we extracted, we 
used a data analysis framework which we 
developed during the protocol development 
stage. The quantitative data analysis was 
conducted in Microsoft Excel. 
KEY FINDINGS 
Which EEs have been conducted for paediatric 
pulmonary diseases? 
There were 22 articles included in our 
systematic review. Seven of the articles were 
cost-effectiveness analysis (CEA) studies, five 
were cost-utility analysis (CUA) studies, two 
were cost-minimisation analysis (CMA) 
studies, and eight were cost analyses. 
What is a systematic review? 
A systematic review is a 
method/process/protocol in which a body 
of literature is aggregated, reviewed, and 
















Where were these EEs conducted? 
Fourteen studies were published in high-income countries  (HICs) and eight in low-middle-income 
countries (LMICs) 
How have these EEs been done? 
Concerns have been raised in literature regarding methodological approaches in child-related 
research. In this systematic review, we found that only 25% of the studies that should have (e.g. 
randomised control trials) reported informed consent reported it. There were also some challenges 
identified in how health was valued in some of the included articles.  
Which diseases did these EEs cover? 
The diseases covered by the EEs were pneumonia, asthma, and TB.  
 Asthma Pneumonia Asthma and Pneumonia TB Total 
High-income 9 3 2 - 14 
Middle-income 1 2 - - 3 
Low-income - 4 - 1 5 
Total 10 9 2 1 22 
 
What is a cost-effectiveness analysis? 
A cost-effectiveness analysis compares 
the costs and effects associated with 
different treatment intervention options 
over a set period through the generation 
of incremental cost-effectiveness ratios 
(ICERs). 
What is a cost-utility analysis? 
A cost-utility analysis compares the 
costs and effects associated with 
different treatment interventions over a 
set period through the generation of 
incremental cost-utility ratios (ICURs). 
 
 
What is a cost-minimisation analysis? 
A cost-minimisation analysis compares 
two interventions which are assumed to 
have the same outcome or effects to 
find out which is of the two is the least 
costly option. 
What is a cost-benefit analysis? 
A cost benefit analysis is a type of 
economic evaluation where costs and 
benefits are both valued in monetary 
terms. 
 
What is a cost analysis? 
A cost analysis compares the costs of two or more alternatives without examining their 
outcomes to find out which is of the alternatives is the least costly option. It can also be the 




When were these EEs published? 
CONCLUSION 
There were more partial EEs conducted than there were full EEs. The EEs were more prominent in HICs than they were in LMICs. Yet, children from LMICs are 
disproportionately affected by pulmonary diseases. We also identified some inconsistencies in how health was valued in the articles we included. We, 
therefore, highlight the need to standardise methods for conducting economic evaluations. We also assert that having more EEs for paediatric pulmonary 
diseases in LMICs could aid in evidence-based decision-making. This could go a long way in informing resource allocation for paediatric pulmonary diseases. 
Thereby reducing the social and economic burden imposed by paediatric pulmonary diseases, particularly in less well-off groups.  
POLICY RECOMMENDATIONS 
 Formulate public health policies that support the uptake of EEs in child-health decision making. 
 Facilitate improvements in paediatric pulmonary disease research in the under-five age group through strengthening the capacity of research 
institutions, particularly in low-income settings where pulmonary diseases are common. 
 Equip health economists to conduct EEs in children through training and workshops. 
 Develop standardised protocols for those intending to carry out EEs for children. 
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